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Abstract 
 
The synthesis and evaluation of novel resveratrol-based nitroxides have been 
explored for the potential treatment of hypertension. New methodology for the direct 
aryl iodination of isoindoline and isoindoline nitroxide using periodic acid and 
potassium iodide in concentrated sulphuric acid was developed. Diiodinated 
tetramethyl and tetraethyl isoindolines and a tetramethyl isoindoline nitroxide were 
prepared in excellent yields (70 – 82%).  A diiodinated tetraethyl isoindoline 
nitroxide was generated from the corresponding nitroxide in modest yield (37%) 
alongside iodinated nitrones. The mono-iodinated species were also generated in 
modest yields (34 – 48%). Incorporation of the nitroxide unit into the structure of 
resveratrol was achieved using palladium-catalysed Heck coupling. Use of the 
previously prepared iodo products 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloyl 18 
and 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22 gave resveratrol nitroxides 
12 and 13 in yields of 50% (optimized) and 1.6% respectively. Preliminary 
evaluation of the resveratrol analogue 12 as a treatment for hypertension was 
undertaken in the DOCA-salt rat model. A reduction in systolic blood pressure as 
well as alleviation of ventricular hypertrophy was observed. A larger study involving 
the DOCA salt rats is currently in progress.  
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 Introduction  
1.0 Antioxidants, Reactive Oxygen Species and Diseases 
 
An antioxidant is a substance that is capable of significantly delaying or reducing 
oxidation of a substrate. In biological systems, the oxidisable substrate can be 
various components of the cell such as proteins, lipids or DNA.
1
 Biological processes 
such as aerobic cellular metabolism and gene expression can produce pro-oxidants 
which are partially reduced derivatives of oxygen (reactive oxygen species or ROS) 
or derivatives of nitric oxide known as reactive nitrogen species. Under normal 
circumstances the body releases antioxidant enzymes and substances such as 
superoxide dismutase, catalase, glutathione peroxidase, vitamin E and vitamin C to 
convert these ROS into neutral non harmful species (see table 1.1)
2,3
, this keeps the 
balance between ROS and antioxidants (Figure1.1 a). 
Table 1.1:  Commonly encountered ROS in the body and their corresponding natural 
antioxidant defense mechanisms.
3
  
Free radicals                                                 Enzymatic scavengers
O2                   Superoxide anion radical       SOD     Superoxide dismutase
OH                Hydroxyl radical                                 2O2  + 2H
+         H2O2 + O2
ROO              Lipid peroxide(peroxyl)        CAT     Catalase (peroxismal bound)
RO                 Alkoxyl                                               2H2O2        O2 + H2O
RS                 Thiyl                                      GTP      Glutathione peroxidase
NO                 Nitric oxide                                         2GHS + H2O2       GSSG + 2H2O
NO2                Nitrogen dioxide                                 2 GSH + ROOH       GSSG + ROH + 2H2O
ONOO            Peroxynitrite
CCl3               Trichloromethyl                      Nonenzymatic scavengers
                                                                       Vitamin A
Non-radicals                                                  Vitamin C (ascorbic acid)
H2O2               Hydrogen peroxide                 Vitamin E (alpha-tocopherol)
HOCl              Hypochorous acid                   Beta-carotene
ONOO            Peroxynitrite                           Cysteine
1O2                  Singlet oxygen                        Coezyme Q
                                                                        Uric acid
                                                                        Flavonoids
                                                                        Sulfhydryl group
                                                                        Thioether compounds
The superscripted bold dot indicates an unpaired electrons and the negative charge indicates a
gained electron. GSH, reduced glutathione; GSSG, oxidised glutathione; R, lipid chain. Singlet
oxygen is an unstable molecule due to the two electrons present in its outer orbit spining in oposite 
directions.  
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An imbalance in concentration between the natural antioxidants and the ROS (in 
favour of ROS) leads to a biological imbalance known as oxidative stress; a term 
used to describe the oxidative destruction of the components of the cell including 
proteins, lipids and DNA (Figure 1.1).
4
 
 
 
 
 
 
 
 
 
 
Figure 1.1:(a) No oxidative stress when ROS and antioxidants levels in the body are 
equal or antioxidants > ROS, (b) Oxidative stress results when the concentration of 
ROS outweighs that of antioxidants. 
 
Decreases in the level of antioxidants, insufficient dietary antioxidants or increased 
production of ROS are some of the factors that cause oxidative stress.
4
 Mild and 
moderate oxidative stress is often nullified by the body’s antioxidants, however, in 
severe cases, oxidative stress can results in apoptosis of the cell.
4
 For this reason, 
oxidative stress is associated with several diseases (Figure 1.2). 
Antioxidants         ROS 
       ROS 
Antioxidants 
(a) 
(b) 
No oxidative stress 
 
Oxidative stress 
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Figure 1.2: Various diseases associated with oxidative stress. 
 
Oxidative stress has been noted to contribute in the pathogenesis of atherosclerosis 
and other cardiovascular diseases. Atherosclerosis is a chronic inflammatory disease 
of the arterial walls that involves formation of plaques in the arterial wall which 
narrows the arterial lumen causing restriction in blood flow (Figure 1.3). 
Experimental data indicates that the presence of oxidized low density lipoprotein 
(LDL) within arterial wall enhances the promotion of atherogenesis.
5
  
Human Diseases 
Neurodegenerative 
Diseases 
 Alzheimer’s Disease 
 Parkinson’s Disease 
 Multiple Sclerosis  
 Ataxia Talangiectasia 
 
Oxidative stress 
(excess ROS e.g. 
H2O2, OH
.
) 
 
Cancers  
 Breast 
 Prostate 
 Lung 
 Stomach  
 Brain 
 Ovary 
 
Cardiovascular Diseases 
 Atherosclerosis 
 Hypertension 
 Heart failure 
 Ischemia-reperfusion 
myocardial injury 
 Stroke and diabetes 
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Figure 1.3: (A) A typical healthy artery, (B) An artery partially blocked with 
plaque.
6
 
 
As indicated by the graph in Figure 1.4, mildly oxidised LDL (MM-LDL) induces 
chronic inflammation whereas highly oxidised LDL (ox-LDL) is cytotoxic.
7
 Studies 
have also shown that phospholipids are susceptible to oxidation by free radicals or 
enzymes such as myeloperoxidase and lipoxygenase and produce molecules that can 
interact with receptors that mediate atherosclerosis or trigger reactions with other 
biomolecules within the blood vessel.  
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Figure 1.4:  Effects of the degree of oxidation of LDL on cells.
7
 
 
In vivo human experiments have also revealed the accumulation of oxidised lipids in 
vessel walls during all stages of atherosclerosis which suggests the possible 
involvement of ROS in the pathogenesis of atherosclerosis.
8
 Oxidative stress has also 
been implicated in the pathogenesis of hypertension with studies showing that 
oxidative stress induced rats develop hypertension which can be reversed by the 
administration of antioxidants.
9
 Other ROS related cardiovascular diseases include 
ischemia-reperfusion myocardial injury, heart failure,
10
 stroke and diabetes.
11
 
 
Evidence from several studies implicate reactive oxygen species in various 
biomolecular interactions that contribute to the multi-stage process of 
carcinogenesis.
12
 Several reports indicate that cancer cells are under a constant state 
of oxidative stress.
13
 Excessive amounts of ROS triggers oxidative damage to lipids, 
proteins and DNA which leads to oncogene transformation, increased metabolic rate 
and mitochondrial dysfunction.
13
 It has also been shown that human tumour cell lines 
produce ROS at a higher rate than healthy cells.
13
 Genetic alteration of DNA is 
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considered to be a critical process in the etiology of cancer with elevated level of 
oxidised DNA lesions previously observed in tumour cells.
14
 Among the main 
damages, ROS induces oxidative modification of DNA bases, DNA strand breakage, 
and the alteration of bases by substituting one base for another. Such changes in 
DNA structure may cause activation of the proto-oncogene or inactivation of the 
tumour suppressor gene. For instance, both in vitro and in vivo studies in animal 
models have shown that ROS causes base substitution (C to T) in the p53 tumour 
suppressor gene.
12
 Such mutations have been observed in up to 60% of non-
melanoma skin cancers in humans leading to the suggestion that ROS may be 
involved in the inactivation of the tumour suppressor gene in humans.
12
 Higher levels 
of oxidatively damaged DNA base products have been observed in breast, lung, 
stomach, colon, ovary and brain cancer infected tissue.
15
 It is yet unclear whether this 
is due to oxidative DNA damage but similar observations have been recorded in the 
benign prostatic hyperplasia where an increase in prostate gland size is thought to be 
related to the emergence of prostate cancer.
15
 
 
In addition, certain studies have shown that ROS induces apoptosis in tumour cells 
(Figure 1.5).
16
 This effect can be reversed when tumour cells are treated with 
antioxidants. For example, increased expressions of the antioxidant proteins catalase 
and peroxiredoxin III have been demonstrated to prevent hydrogen peroxide–induced 
apoptosis in tumour cells.
16
 Furthermore, ROS is known to induce senescence, a 
disturbance in metabolism that give rise to deterioration and death of cells. An 
example of this is the suppression of cell growth by hydrogen peroxide through the 
initiation of cell cycle check-point arrest by suppressing the S-phase of the cell 
Chapter one 
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cycle.
16
 Therefore ROS can act as a tumourigenic and anti-tumourigenic agents with 
its action determined by the origin of the cell and tissue upon which it is acting. 
 
Figure 1.5:   Schematic diagram showing the various processes that produce ROS 
and the cellular processes leading to the induction of apoptosis or anti-apoptosis.
16
 
 
Furthermore, oxidative stress plays a crucial role in the etiology and pathogenesis of 
neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), multiple sclerosis and ataxia telangiectasia.
12
 Susceptibility to these 
neurodegenerative diseases increases with age and it has been found that with 
increasing age, the oxidative products from lipids, nucleic acids proteins etc also 
increase.
17
 In AD, high oxidative stress has been associated with the protein amyloid 
β, a major component of the senile plaque found in the brain of AD afflicted people. 
In vitro studies have shown that this protein generates free radicals followed 
subsequently by lipid and protein oxidation and it is associated with neurotoxicity; 
thus the postulation that amyloid β plays a major role in the development of AD.12,15  
In the brain of PD patients, increased lipid peroxidation,
18
 oxidative DNA damage 
and protein damage have all been observed.
19
 Similarly, oxidative stress has been 
observed in multiple sclerosis
20
 and ataxia talangiectasia.
21
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Due to the role played by oxidative stress in the pathogenesis of cardiovascular 
disease, cancer, neurodegenerative diseases and associated disorders, the use of 
antioxidant therapy for treatment and prevention of these diseases has been widely 
explored. Epidemiological studies have shown that an increase in antioxidant intake 
corresponds to a reduction in clinical expression of coronary artery diseases. 
Individuals subjected to high dietary intake of vitamin C, E and beta-carotene 
showed lower risk of coronary heart disease and longer life expectancy.
22
 In the 
study of atherosclerosis prevention, a combination of α-tocopherol and aspirin 
significantly reduced carotid intima-media thickness in hypercholesterolemic 
males.
10
  
 
Treatment of bladder cancer cells with high doses of resveratrol significantly reduced 
cell proliferation by inducing apoptosis and cell cycle arrest whereas lower doses 
prevented apoptosis hence providing protection against cardiovascular diseases.
23
 
Clinical trial studies revealed treatment with high doses of vitamin E and C reduces 
the risk of developing AD.
24
 In PD, both moderate and high dietary intake of vitamin 
E have been shown to exert neuroprotective influences
25
 whereas a combination of 
vitamin E and selenium has been shown to prevent lipid peroxidation in multiple 
sclerosis.
26
 However, in the literature, other studies dispute the efficacy of 
antioxidants in the treatment of these diseases. For instance a meta-analysis of 
studies involving a randomised trial of vitamin E and β-carotene found both 
antioxidants did not lower cardiovascular mortality compared with the control, in 
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fact β-carotene was observed to slightly increase the risk of cardiovascular death.27 
Studies with vitamin C and β carotene in PD patients did not reveal any 
neuroprotective effect.
25
 
Resveratrol is a polyphenolic antioxidant that has been shown to display beneficial 
health effects in cardiovascular diseases, cancer and neurodegenerative diseases
28
 in 
several mammalian animal models.
29
 Currently, numerous studies are being 
undertaken in animal or animal cell models to ascertain the efficacy and mechanism 
of action of resveratrol. The next section reviews some of the relevant studies that 
have been carried out to study the effects of resveratrol on cancer, cardiovascular 
disorders and neurodegenerative diseases. 
  
1.1. Resveratrol 
Resveratrol 1 (3,4’,5-trihydroxystilbene) is a naturally occurring stilbenoid that is 
produced by plants in response to fungal attack, injury or stress.
30
 At least 72 species 
of plants produce resveratrol including peanuts, mulberry skins and grape skins 
(hence the presence of resveratrol in red wine).
31
 About 5 to 10% of the biomass of 
grape skin is resveratrol with concentrations ranging from 2 to 40 µM in red wine.
32
  
 
 
Figure 1. 6: Examples of plants known to contain resveratrol. 
Peanuts Mulberry fruits Grape fruits 
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The chemical structure of resveratrol consists of a resorcinol ring linked to a phenolic 
ring by an ethylene group (Figure 1.7). It exists as cis and trans isomers and 
exposure to UV light facilitates the conversion from the trans to cis isomer. The cis 
isomer is not currently available commercially and it has little biological activity. 
However the pharmacological effects of the trans isomer have been extensively 
studied in vitro, ex vivo and in vivo.
33
 This review will examine trans-resveratrol and 
from now onwards it will simply be referred to as resveratrol. 
 
Figure 1.7: Chemical structure and numbering of trans-resveratrol (1) 
 
Research into the biological activity of resveratrol was primarily sparked by the 
observation that despite high intakes of saturated fat by French people, they have low 
incidences of coronary heart disease, a phenomenon which is commonly referred to 
as the “French paradox”.33 Regular consumption of red wine by the French has been 
proposed as the explanation for this observation and resveratrol has been identified 
as the compound possibly responsible for the observed cardioprotective effect of red 
wine.
34
 Indeed, several reports have shown that resveratrol can prevent or slow the 
progression of several disorders including cardiovascular diseases, cancer, 
neurodegenerative diseases and extends the life span of organisms from yeasts to 
vertebrates.
35,36
 The mechanism of action of resveratrol is not yet clear, in vitro 
attempts to demonstrate its beneficial actions have largely been successful with 
several direct targets identified.
35
 However, pharmacokinetic studies have shown that 
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resveratrol is rapidly metabolised by the circulatory system leading to questions 
about the relevance of the typically high concentrations used for in vitro studies. It is 
yet to be established whether it is resveratrol or its metabolites that accumulate in 
tissues are responsible for the effects seen in the in vitro experiments.
35
 
 
1.1.1. RESVERATROL AND HEART DISEASE 
 
In addition to predisposing factors like age, sex and genetics, other risk factors such 
as inflammation, oxidative stress and endothelial damage contribute to the 
development of cardiovascular diseases. In vitro studies and experiments on animal 
models suggest several possible mechanisms for the improvement of cardiovascular 
health by resveratrol. First, resveratrol induces the expression of nitric oxide (NO) 
synthase, the enzyme that catalyses the synthesis of the vasodilator NO in human 
vascular endothelial cells. Nitric oxide decreases the expression of the 
vasoconstrictor endothelia; inhibits LDL oxidation, platelet aggregation and cell 
proliferation.
28,37
 
 
Inhibition of platelet aggregation is one of the accepted mechanisms by which 
resveratrol acts against coronary heart diseases.
37
 Platelets are cells with no nuclei 
that are made in the bone marrow; they are involved in blood clot formation to stop 
bleeding at wound sites. A number of factors such as adenosine diphosphate, 
collagen and thrombin activate platelets which change shape and aggregate to seal 
the damaged blood vessels. If there is too much platelet blood clotting,obstruction of 
blood vessels occurs thereby resulting in cardiovascular disease. Resveratrol has 
been shown to inhibit lipopolysaccharide and lipopolysaccharide + thrombin 
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stimulated platelet adhesion to collagen and fibrinogen.
38
 Both in vivo and in vitro 
studies have shown that resveratrol inhibits adenosine diphosphate, collage and 
thrombin stimulated human platelet aggregation.
38
 Rabbits that received resveratrol 
have reduced aggregation of platelets while under a high cholesterol diet.
38,39
 
 
Beneficial cardiovascular effects of resveratrol may arise from its vasorelaxation 
ability. In a study by Naderali et al, resveratrol induced vasorelaxation in the 
mesenteric artery and the main uterine artery of female guinea pigs that were 
previously administered with noradrenaline and potassium chloride to induce 
constriction.
40
 In another study, resveratrol caused vasorelaxation in the aortic rings 
of rats that had noradrenaline and phenylephrine induced constriction.
38
 Resveratrol 
causes vasorelaxation through stimulation of the Ca
2+
 dependent K
+
 channels.
35
 It 
also mediates nitric oxide signaling in the endothelium through hindrance of 
NAPH/NADPH oxidase activity giving rise to interference with the basal superoxide 
production; this causes reduction in nitric oxide inactivation resulting in 
vasorelaxation.
35
 In vivo studies found that resveratrol stimulates the synthesis of 
both endothelial and inducible nitric oxide synthase.
35
 
 
Oxidative modification of LDL has been shown to play a central role in development 
of atherosclerosis.
41
  It has been reported that resveratrol combats oxidative damage 
to LDL by chelating metallic copper ions.
42
 Metals are pro-oxidants as they are 
capable of transferring electrons that facilitate the formation of free radicals from 
PUFA and hydroperoxides. An overload of copper in the body has been shown to 
give rise to an over production of ROS which causes oxidative stress and  damages 
macromolecules such as lipids.
42
 Resveratrol as a free radical scavenger is capable of 
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oxidising ROS such as hydroxyl, superoxide and metal induced radicals.
43
 In vivo 
experimentation has shown that resveratrol inhibits both metal ion dependent and 
independent peroxidation of porcine lipids.
44
 It also induces antioxidant enzymes like 
catalase, superoxide dismutase (SOD) and thioredoxin.
45
 In particular, it regulates the 
activity of the mitochondrial SOD called manganese SOD that normally counteracts 
the formation of ROS in the mitochondrial electron transport chain.
45
 Resveratrol has 
been shown to stop ROS formation through suppression of pro-oxidant genes like 
nicotinamide adenine dinucleotide, phosphate oxidase and myeloperoxidase,
45
 
 
1.1.2. RESVERATROL AND CANCER 
Jang and colleagues’ finding that resveratrol inhibits carcinogenesis at multiple 
stages inspired research into using resveratrol as a potential cancer chemopreventive 
agent in humans.
46
 They reported up to a 98% reduction in skin tumour per mouse 
after topical application of resveratrol.
46
 Since then a number of studies involving rat 
and mouse models have revealed the anti-tumor and anti-inflammation activity of 
resveratrol in a wide variety of tumour cells including breast, colon, prostate and 
lung cancer cells.
47,48
  However, despite its anticancer activity, resveratrol possesses 
relatively low potency with typically higher dosages required to achieve significant 
anticancer activity.
49
 
 
In breast cancer cells resveratrol has been found to inhibit the growth of estrogen 
receptor-positive MCF-7 and KPL-1 cells in a dose dependent manner.
50,51
 The 
estrogen receptors are activated by the enzyme estrogen and it has been reported that 
the progression of significant numbers of tumours depend upon estrogen.
52
 At low 
concentrations, resveratrol activates cell proliferation whilst high concentrations 
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inhibit the estrogen receptors.
51
 Resveratrol has also been shown to inhibit the 
insulin-like growth factor 1 receptor (IGF-1R) mediated cell migration and invasion 
of the MDA-MB 435 human breast cancer cells.
53
 IGF-1R is a protein kinase 
implicated in the development and progression of malignant tumours with higher 
level of IGF-1 a predictor of breast cancer risk in premenopausal women.
53
 Although 
in vitro studies have shown that resveratrol inhibits the growth of 4T1 breast cancer 
cells,
54
 so far, in vivo replication of the experiments showed resveratrol has no effect 
on the growth of the cells.
54
 
 
Resveratrol suppresses colon cancer cell proliferation and it has also been shown to 
induce apoptosis in cells.
55
 Administration of 78.9 ± 5.4 µM of resveratrol to HT-29 
colon cancer cells induced up to a 50% inhibition of growth.
55
 Growth suppression 
has also been observed in other colon cancer cells like caco-2, HCT-116 and 
SW480.
56
 The mechanism of anti-proliferation involves blocking the transition of 
cells from G1/S to G2/M (check points at which the regulation of cell proliferation is 
conducted which are defective in colon cancer cells).
56
 In human colorectal 
carcinoma cells, resveratrol has induced apoptosis by activation of the enzyme 
caspase in in vivo and in vitro experiments.
56
 The caspases are a family of cysteine 
proteases that mediate programmed cell death by cleaving a series of essential 
intracellular proteins leading to cell death.
57
 Resveratrol has also been known to 
trigger apoptosis in HT-29 cells through lysosomes and the endoplasmic reticulum 
and induction of the proapoptosis gene CHOP/GADD153.
56
 
 
Several in vitro studies have demonstrated the anti-proliferative or pro-apoptotic 
effects of resveratrol in human prostate cancer cells. Resveratrol has been shown to 
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inhibit the growth of LNCaP, PC-3 and DU-145 prostate cancer cells in a 
concentration dependent manner, with PC-3 and DU-145 cells requiring 10-fold 
concentrations compared to the 2.5 x 10
-6
M required for LNCaP cells.
58
 Resveratrol 
inhibits the growth of androgen dependent prostate cancer cells by influencing 
androgen receptors. Androgen receptors stimulate proliferation and impede apoptosis 
of normal prostate epithelial cells and androgen dependent cancer cells. Resveratrol 
acts on the androgen dependent prostate cancer cell line LNCaP by repressing 
expression of the androgen receptor, the androgen receptor specific co-activator 
ARA70 and various androgen receptor regulated genes such as PSA.
32
 Higher levels 
of androgen have also been known to induce ROS formation, thereby exposing cells 
to oxidative stress and subsequent DNA damage. Although other studies have shown 
that resveratrol does not have an effect on the expression of androgen receptors, 
some studies demonstrated that it did decrease androgen receptor levels in a time and 
dose dependent manner by targeting the androgen inducible genes.
58
 Radiotherapy is 
one of the methods that are currently used for the treatment of prostate cancer, 
however, as prostate cancer cells are radioresistant, high radiation doses are 
required.
59
 Due to excessive exposure to radiation other side effects such as 
impotence, urinary dysfunction and rectal symptoms may arise.
59
 Resveratrol 
sensitises DU145 and PC-3 prostate cancer cells to radiation.
59
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1.1.3. RESVERATROL AND NEURODEGENERATIVE DISEASES 
In Alzheimer’s disease (AD), resveratrol has been shown to promote the degradation 
of amyloid β, the protein believed to play a very important role in facilitating the 
formation of plaques that eventually lead to neurodegeneration.
60
 As oxidative stress 
is known to facilitate the formation of amyloid β which promotes plaque formation,61 
the treatment with an antioxidant should diminish plaque formation. Administration 
of resveratrol to AD infected mice for 45 days by Karuppagounder et al led to a 
reduction in plaque formation in the brain region of the cortex (48%), the striatum 
(89%) and the hypothalamus (90%).
61
 The same study revealed that resveratrol 
promoted gluthathione degradation releasing cysteine and causing up to a 54% 
increase in the intracellular cysteine concentration. Cysteine is known to act as an 
antioxidant, in fact an N-acetylcysteine has been shown to protect SHSY-5Y 
neuroblastoma cells from oxidative damage due to hydrogen peroxide, UV light and 
amyloid-β1 – 42.
61
 Cysteine has also been shown to interfere with the formation and 
extension of amyloid β fibrils which lead to a reduction in amyloid β secretion in 
different cell lines.
62
 
 
Oxidative stress, apoptosis and aging are some of the important factors which 
contribute to the development of Parkinson’s disease (PD), which is characterised by 
degeneration of the dopaminergic neurons in substantia nigra.
63
 Inflammation has 
been proposed to aid in the progression of the disease; the enzyme cyclooxygenase-2 
(COX-2) and tumor necrosis factor-alpha (TNF-α) are both pro-inflammation 
cytokines which have been observed to be upregulated in PD patients.
63
 Treatment of 
rats with 6-hydroxydopamine (6-OHDA) induced dopaminergic neuron degeneration 
and subsequent treatment with resveratrol revealed a reduction in damages to the 
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substantia nigra, and a decrease in COX-2 and TNF-α was also observed.63 
Resveratrol has also been shown to decrease lipid peroxidation and lower dopamine 
loss in PD rat models.
64
 
 
Resveratrol has also shown promising therapeutic effects in other 
neurodegenerative diseases. In Huntington’s disease (HD) , an autosomal 
dominant neurodegenerative disease characterised by motor and cognitive 
impairment, resveratrol increases the expression of the PPARY co-activator-1 α 
(PGC-1 α)  in mice.65 PCG-1 α is a transcriptional co-activator involved in the 
modulation of cell metabolic processes which has been suspected to cause the 
mitochondrial dysfunctions associated with HD.65 ,6 6 The mitogen-activated 
protein kinase signalling has been implicated in HD particularly the Ras-
extracellular signal-regulated kinase (ERK) cascade; there is strong evidence 
suggesting ERK cascade provides neuroprotection while inhibition triggers cell 
death.67  In a study, treatment of HD cell model PC1 2  with resveratrol led to 
activation of ERK.67 Although further experimentation with animal models is 
required, this result suggests the relevance of resveratrol for HD treatment.  
Experimental data also showed resveratrol to be a promising treatment for other 
neurodegenerative diseases including amyotrophic lateral sclerosis6 8 and multiple 
sclerosis.
69
  
 
As discussed above, antioxidant intervention in disorders involving oxidative stress 
may provide effective therapeutic strategies to combat the symptoms associated with 
Chapter one 
33 
 
radical damage. The low toxicity, high stability and unique chemistry of nitroxides 
make them ideal candidates in this area due to a number of potential antioxidant 
mechanisms. Nitroxides are a class of free radical containing compounds which act 
as both free radical scavengers and antioxidants. They have been known to mimic the 
antioxidant enzyme SOD, oxidise reduced metals and terminate free radical chain 
reactions. Like resveratrol, the antioxidant and electron scavenging properties of 
nitroxides are being explored for the treatment of cancer, cardiovascular diseases and 
cancer. The next section discusses some of the important relevant biological studies 
that have been reported in the literature regarding nitroxides. 
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1.2. NITROXIDES 
 
1.2.1. OVERVIEW 
 
Molecules which contain one or more unpaired electrons are called free radicals. 
Compounds with unpaired electrons are generally more unstable than their 
corresponding paired counterparts and are therefore generally more reactive than 
non-radical species.
70
 Nitroxides (nitroxyls) are a class of free radical with an N,N-
disubstituted nitrogen atom bound to a one valent oxygen atom.
71,72
 The single 
delocalised electron is shared between the oxygen and nitrogen atoms as illustrated 
by the resonance structures in Scheme 1.1. 
 
 
Scheme 1.1: Resonance structures of the nitroxide group. 
 
Although the substituents R1 and R2 can be a primary, secondary or tertiary alkyl 
group, nitroxides such as 2 (bearing tertiary alkyl groups) are more stable than 
nitroxides bearing primary or secondary alkyl groups which are susceptible to 
disproportionation to form the corresponding nitrone 3 and hydroxylamine 4 
(Scheme 1.2).
71
 Thus, nitroxides with α-hydrogens decompose to nitrones through 
the transfer of a H
• 
radical to another nitroxide molecule thereby producing an 
hydroxylamine as a second decomposition product.
73
 The absence of a substituent on 
the oxygen atom contributes to stability in the sense that the NO bond in the 
nitroxide is not subjected to conformationally-driven destabilization as seen in an 
oxoaminyl radical 5.
73
 Symmetric dimers have never been observed between 
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nitroxide radicals because delocalization of unpaired electron makes the nitroxide 
structure more stable than the O-O bond of the dimer (R2NOONR2).
72
 
 
Scheme 1.2: Disproportionation reaction of nitroxides 
 
 
Although nitroxides with quaternary carbon-based substituents are quite stable, 
structures with π conjugated substituents are susceptible to degradation. For example, 
while nitroxides bearing a di-t-butyl substituent are stable, t-butyl phenyl nitroxide is 
not as stable because the unpaired electron can be delocalised onto the aromatic ring 
thereby activating the para-position for attack by a second nitroxide radical, which 
results in the formation of a dimer which immediately degrades
73,74
 (Scheme 1.3). 
Some examples of more stable nitroxides are 2,2,5,5-tetramethylpyrrolidine-N-oxyl 
(PROXYL 6), 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO 7) and 1,1,3,3-
tetramethylisoindol-2-yloxyl (TMIO 8). These nitroxides contain no α hydrogen 
atoms and there are also no destabilising substituents present. This robustness allows 
these type of structures to be isolated and used for various applications.
75
 
 
The isoindoline based nitroxide 8 possesses distinct advantages over the 
commercially available piperidine and pyrrolidine based nitroxides. The rigidness 
that results from the fused aromatic ring makes it resistant to ring opening reactions 
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and has been shown to confer to it thermal and chemical stability in polymers.
76
 
Additionally, substitution reaction can easily be carried out on the aromatic ring 
system and often with little impact on the reactivity or stability of the nitroxide 
moiety.
77
 Therefore more complex structures based on the isoindoline nitroxide can 
easily be made without significantly altering the chemistry of the nitroxide moiety. 
 
 Scheme 1.3: Degradation pathway for a nitroxide bearing a phenyl substituent. 
 
 
 
 
1.2.2. ANTIOXIDANT PROPERTIES OF NITROXIDES 
As mentioned above, the mechanisms underlying the progression of disorders such 
as neurodegenerative diseases, cancer and cardiovascular diseases are either directly 
or indirectly linked to oxidative stress (resulting from the excessive production of 
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ROS). Although biological systems possess antioxidant enzymes such as SOD, 
catalase and gluthathione to combat oxidative stress, under certain conditions these 
protective defence mechanisms can be overwhelmed due to the excessive production 
of ROS. Nitroxides have been known to participate in redox chemistry as illustrated 
in Scheme 1.4 where they can be reduced to an hydroxylamine or oxidised to an 
oxoammonium cation.
78
 The ability of nitroxides to shuttle between different 
oxidation states provides the reducing equivalents necessary to detoxify various 
reactive oxygen and reactive nitrogen species.  
 
Scheme 1.4: The nitroxide redox cycle. 
 
Nitroxides have been shown to mimic the activity of the enzyme SOD. SOD 
participates in the detoxification of the free radical superoxide (O2
.-
), but because of 
its large molecular weight, it cannot pass through the cell membrane.
79
 Nitroxides, on 
the other hand, can easily pass through cell membranes.
79
 Nitroxides are also known 
to scavenge carbon and oxygen centered radicals and they are also known to inhibit 
transition metal-mediated damage by oxidising the transitional metal ions such as Cu 
(I) and Fe (II). This prevents the Fenton reaction from occurring, which can generate 
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hydroxyl radicals (Equation 1). Equation 2 demonstrates the oxidation of Fe
2+ 
by a 
nitroxide.
80,81
 
 
Nitroxides inhibit lipid peroxidation. There are three stages of lipid peroxidation - the 
first initiation involves the formation of a lipid radical and can be triggered by free 
radical (X
•
) oxidising a cellular lipid (LH) (Equation 3) or other agents acting 
directly on the lipid such as ionising radiation and smoking.  
 
The second stage of lipid peroxidation is propagation which involves a series of 
reactions (Equations 4-7) that are dependent on the availability of oxygen. Most of 
the biologically induced damage to lipids happens during this stage with the 
reactions continuing until all oxygen is depleted.
79,82
 
 
 
The last stage of lipid peroxidation involves the termination of chain reactions and 
occurs when oxygen or the other substrates are depleted (see Equations 8 and 9).  
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Nitroxide 3 and hydroxylamine 5 prevent lipid peroxidation by quenching the radical 
initiator (Equations 10 and 11) and preventing the radical propagation step by 
reducing the oxidised lipids (Equations 12-14).
79
 
 
 
 
The iron contained in hemoproteins like myoglobin and haemoglobin can undergo 
oxidative reaction with hydrogen peroxide to produce the O2
.-
 free radical. Nitroxides 
have been shown to act like the enzyme catalase by pre-emptively decomposing 
hydrogen peroxide into water and oxygen thereby preventing formation of reactive 
oxygen species.
83
 
 
Due to their antioxidant activities in biological systems, nitroxides are being 
examined as possible treatments for several ailments including cancer and 
cardiovascular and neurodegenerative diseases. One advantage of nitroxides over 
other antioxidants is their reversibility between different oxidation states. 
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1.2.2.1. NITROXIDES AND CARDIOVASCULAR DISEASES 
In vivo studies involving intraperitoneal administration of various nitroxides 
including TEMPOL 9 and 3-carbamoy-PROXYL 10 to rats caused a decrease in 
their systemic blood pressure.
84
 Just like SOD, the nitroxide TEMPOL 9 has been 
observed to increase the amount of bioavailable nitric oxide (NO), a biological 
messenger known to cause vasodilation leading to decrease in arterial pressure.
84
 In a 
separate study, TEMPOL 9 normalised blood pressure of spontaneously 
hypersensitive rats however when NO production was inhibited no antihypertensive 
activity of TEMPOL 9 was observed. This observations indicates that the mechanism 
of action of nitroxides involves NO.
80
 Nitroxides also inhibit the production of 
myeloperoxidase mediated hypocholorus acid (HOCl).
85
 HOCl is normally an 
antimicrobial however it has been linked to the initiation and development of 
atherosclerosis as it produces a highly atherogenic oxidised form of low-density 
lipoproteins that is used by macrophages to generate lipid laden cells, promotes 
extracellular matrix formation and destroys anti-atherogenic properties of high-
density lipoproteins.
85
 4-Amino TEMPO 11 inhibits the production of HOCl with an 
IC50 value of about 1 µM.
85
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1.2.2.2. NITROXIDES AND CANCER 
 
When administered in synergy, TEMPOL nitroxide 9 has been shown to improve 
clinical effects of the prototypical anthracycline antibiotic doxorubicin towards 
breast cancer cell lines.
86
 Anthracyclines are a class of drugs used in the treatment of 
various types of cancer, however, the limitation of this class of drug is after the first 
administration, the tumour cells develop resistance to the drug and consequently 
subsequent administration does not exert any effect.
86
 In a separate study with human 
and rodent cancer cell lines, TEMPOL nitroxide 9 was more effective in inhibiting 
the growth of tumour cells than normal cell lines after a duration of 4-days.
87
 The 
same study concluded that the antiproliferative action of TEMPOL 9 is due to the 
presence of the unpaired electron, since administration with the free radical 
scavenger N-acetylcysteine reduced activity significantly. In a model of the human 
cancer syndrome, elongation of lifespan of atm-deficient mice from 30.1 weeks to 
62.4 weeks was observed after being fed with TEMPOL 9 in their food.
88
 TEMPOL 
9 reduced the level of ROS and the mice displayed a reduction in weight with the 
latter suggesting the anti-proliferative activity of TEMPOL 9.
88
 The induction of 
apoptosis by nitroxides appears to proceed through activation of the caspase enzyme 
family with the activation of these enzymes signalling mitochondrial cell apoptosis. 
Treatment of prostate cancer cell line (LNCaP) with a 5.0 mM of TEMPO 7 induced 
the activity of caspase-3 by up to 15-fold in 4 hrs.
89
 Although more work needs to be 
done, these studies highlight the potential of nitroxides as anti-cancer agents. 
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1.2.2.3. NITROXIDES AND NEURODEGENERATIVE DISEASES 
The protein β-amyloid (Aβ) is the major constituent in the plaque which 
characteristically forms in the brain of Alzheimer’s disease (AD) patients. It is 
believed that Aβ associated free radical oxidative stress triggers lipid peroxidation, 
protein oxidation and DNA oxidation. Hence the postulation that Aβ induced 
oxidative stress leads to neurodegeneration in the brain of AD patients.
90
 Superoxide 
and hydroxyl free radicals associated with Aβ1-42 have been observed to induce cell 
death in the neuroblastoma SH-SY5Y cells. In a study, pre-treatment of SH-SY5Y 
cells with TEMPOL 9 for 24 hrs before exposure to Aβ1-42 led to inhibition of 
superoxide anion and hydroxyl radical generation and therefore reduced apoptosis.
91
 
The mechanism of action of the inhibition is thought to be through mimicking the 
properties of SOD as described at the beginning of this chapter. In Parkinson’s 
disease (PD), administration of TEMPOL 9 to the MN9D dopaminergic cells 
reduced 6–OHDA induced cell death from 30% to 5%.92 Parkinson’s disease is 
characterised by loss of the dopaminergic neurons in the par compacta of the 
substantia nigara. It is postulated that the pathogenesis of PD involves oxidation of 
dopamine into ROS by hydrogen peroxide, superoxide and hydroxyl radicals.
92
 
Reports from autopsies of PD patients indicate deficiency of SOD, therefore 
treatment with a nitroxide appears to be a logical pathway since nitroxides can mimic 
SOD. 
 
Even though both nitroxides and resveratrol act as antioxidants in biological systems, 
there are no reported cases of the biological study of the effects of combining 
resveratrol with nitroxides in an animal or cell model. It is envisioned that coupling 
resveratrol with a nitroxide will confer the resultant analogue with enhanced ability 
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to act as an antioxidant and a free radical scavenger. Moreover the nitroxide portion 
of the molecule can reversibly undergo redox reactions at physiological conditions. 
As the work in this project was being carried out, Kalai et al reported a study into the 
effects of incorporating five- and six-membered ring nitroxides and isoindoline 
nitroxides into the structure of resveratrol i.e. compounds 12,56, 57 and 58.
93
  
 
Kalai and co-workers found that the presence of the nitroxide unit did not alter the 
antioxidant activity of the parent resveratrol structure. The antioxidant activity was 
determined using the Trolox Equivalent Antioxidant Capacity (TEAC) technique. 
TEAC is a technique for determining the antioxidant capacity of a given substance 
by comparing its value to that of the antioxidant Trolox. Furthermore, an anti-
inflammatory study conducted on inflammation induced RAW264.7 mouse 
macrophage cells indicated that the analogues had activities comparable to that of 
resveratrol.
93
 As of now there are no known in vivo studies on the effects of 
incorporation of a nitroxide moiety into the resveratrol structure. Thus the aim of this 
work was to prepared nitroxide-based resveratrol analogues which could be 
evaluated as antioxidant treatments in an in vivo rat based model for hypertension. 
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1.3 NITROXIDES, RESVERATROL AND HYPERTENSION 
The earliest study of the effects of nitroxides on the blood pressure of hypertensive 
animal models was carried by Hahn and colleagues.
84
 They intraperitoneally 
administered various nitroxides to C3H mice and observed a reduction in the mean 
systemic blood pressure.
84
 The majority of the subsequent reported studies testing the 
effects of nitroxides on hypertension have been carried out using TEMPOL 9.
94
 In a 
similar fashion to other cardiovascular diseases, reactive oxygen species have been 
recognized as very important mediators in the development of hypertension. 
Increased vascular ROS activity reduces the bioavailability of NO which in turn 
leads to decreased endothelium dependent vasorelaxation.
95
 TEMPOL 9 acts through 
the induction of the bioavailability of NO.
80
 Administration of TEMPOL 9 to aorta 
with acetylcholine induced reduced NO dependent vasodilatation which caused 
normalization of vasodilatation.
96
 Furthermore, both short and long term oral 
administrations of TEMPOL 9 to rats and miniature pigs prevented the development 
of high blood pressure.
96
 Welch et al reported up to 50% reduction of the mean blood 
pressure of spontaneously hypertensive rats after intravenous or oral administration 
of TEMPOL 9.
97
 They also registered up to 31% reduction in the concentration of the 
reactive oxygen species.
97
 Administration of 15 mg/Kg of TEMPOL 9 for 21 days to 
DOCA-salt hypertensive rats (see Chapter 4 for more details) lowered the free 
radical concentration and alleviated hypertension.
98
  
 
Due to its vasorelaxant effects on blood vessels, resveratrol is a therapeutic target for 
the treatment of hypertension.
99
 Its mechanism of action appears to be through the 
mediation of NO inhibition of contractile response to noradrenaline.
40,100
 This is 
illustrated by the cessation of the inhibitory effects when the blood vessels were 
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pretreated with an NO synthase inhibitor before the administration of 
resveratrol.
100,101
 Administration of resveratrol also induces an increase in the activity 
of the enzyme NO synthase.
101
 Several whole animal studies of the effects of 
resveratrol on hypertensive animal models have been carried out. For instance, 
treatment of hypertensive Sprague-dawley rat models with resveratrol caused a 12% 
fall in the systolic blood pressure; more so, protection against hypertension induced 
cardiac hypertrophy was also observed.
102
 Recently, oral administration of 1 
mg/kg/day of resveratrol to DOCA-salt hypertensive rat models for a period of 28 
days resulted in a decrease of cardiac fibrosis and inflammatory cell infiltration. 
Moreover, resveratrol attenuated the increased blood pressure.
103
 Currently there are 
no reported studies on the effects of hybrid compounds of resveratrol bearing 
nitroxides on hypertension. Given that both resveratrol and nitroxides display anti-
hypertension activities in animal models, in this project, the synthesis and biological 
effects of compounds containing both these units will be explored in a hypertensive 
DOCA-salt rat model. 
 
 
1.4. PROJECT OUTLINE 
The aim of this project was to synthesise analogues of resveratrol which incorporate 
the isoindoline based nitroxide 1,1,3,3-tetramethylisoindolin-2-yloyl 8. In target 
compound 12, the phenolic ring of resveratrol has been replaced by the isoindoline 
nitroxide 8 whilst target compound 13 also bears a dihydroxystyrene unit on position 
6 of the aromatic ring of the isoindoline nitroxide moiety. 
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It was envisioned that the resveratrol structures bearing conjugated nitroxide units 
will act as both an antioxidants and a free radical scavengers, making them more 
effective antioxidants for counteracting oxidative stress associated with 
cardiovascular diseases, cancer or neurodegenerative diseases. Resveratrol is also 
known to readily cross cell membrane including the blood brain barrier (BBB)
104
 
whereas nitroxides have limited permeability in the BBB.
105
 Therefore, the 
resveratrol portion of the hybrid molecule, in addition to being an antioxidant, might 
also act as a vehicle for delivering the nitroxide into the brain. The isoindoline 
nitroxides are chemically and thermally stable over a wide range of environmental 
conditions;
106
 they have also been shown to possess low cytotoxicity and a moderate 
rate of metabolism in the Chinese hamster ovary (CHO) cells.
107
 An advantage of the 
isoindoline based nitroxide over the commercially available piperidine and 
pyrrolidine based nitroxide is that their structural diversity can easily be expanded by 
aromatic substitution to generate more complex structures for a range of 
applications.
108
 
 
Previously Chan V et al observed decreased inflammation, cardiac fibrosis and 
improved cardiac and vascular functions in hypertensive rats orally administered 
resveratrol in water.
103
 The current project aims to replicate their study with nitroxide 
incorporated resveratrol analogues. 
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The target compounds 12 and 13 should be accessible using the palladium-catalysed 
Heck reaction (Scheme 1.5) from the corresponding iodinated nitroxides (18 or 22) 
and the styrene derivative 33. Due to the electron rich nature of the isoindoline 
system, aryl iodides have been shown to provide a significant improvement in yield 
over the corresponding aryl bromides in palladium-catalysed reactions.
52
 An 
advantage of the Heck reaction is the selective formation of the trans product. The 
Heck reaction has been previously employed by several groups to synthesise 
resveratrol in excellent yields.
109,110
 The reaction is often performed using 
dimethylformamide (DMF) as solvent with triphenylphosphine as the ligand and 
potassium carbonate as the base in the presence of a palladium acetate catalyst. 
 
 
Scheme 1.5: Proposed synthetic approach to prepare target compounds 12 and 13. 
(a) = Pd(OAc)2, K2CO3, PPh3, DMF, 120 
o
C 
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In order to synthesise the target compounds 12 and 13, the iodinated precursors must 
first be in hand. Chapter 2 will discuss the development of methodology to directly 
obtain aryl iodide functionalized isoindoline nitroxides.  
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2.0. IODINATED ISOINDOLINE NITROXIDE MOIETIES  
 
The investigation of new methodology for the preparation of aryl iodide 
functionalized nitroxides was required as novel iodinated precursors were needed for 
the subsequent Heck coupling reactions to generate the desired nitroxide-resveratrol 
hybrid molecules.  
 
2.1 Synthesis of 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl (18). 
 
Access to mono-iodo nitroxide 18 can be gained following previously established 
methods within the Free Radical Research Group at QUT (Scheme 2.1).
76
 The first 
step in this procedure involves a condensation reaction between benzylamine and 
phthalic anhydride. After heating at reflux for an hour in acetic acid, and following 
recrystallisation from ethanol, N-benzylphthalimide (14) was obtained in high yield 
(94%, Scheme 2.1).  
 
 
Scheme 2.1:  (i) BnNH2/AcOH, reflux (ii) MeMgI/PhCH3, 110 
o
C (iii) AlCl3, Br2, 
DCM, 1Hr (iv) n-BuLi, I2, -78 
o
C (v) mCPBA, DCM, 0 
o
C (0.5Hr) –RT. 
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The reaction begins with the nucleophilic addition of benzylamine to the phthalic 
anhydride to form intermediate compound 38 (Scheme 2.2). Subsequent ring closure 
produces the geminal diol containing intermediate 39 which, due to the unstable 
nature of the geminal diol, undergoes proton transfer between the diols to give 
intermediate 40. Finally, the loss of a water molecule gives the desired compound 
14.
111,112
 The identity of the compound was confirmed using 
1
H NMR spectroscopy 
with the isoindoline aromatic hydrogens (5-H and 6-H) resonating at 7.87 ppm (lit.
111
 
7.86 ppm) and 4-H and 7-H appearing at 7.73 ppm (lit.
111
 7.73 ppm). The 
characteristic benzyl CH2 protons resonated as a singlet at 4.87 ppm (lit.
111
 4.9 ppm). 
The signal for the benzyl aromatic protons 3-H
’
 and 7-H
’
 appeared at 7.46 ppm 
(lit.
111
 7.45 ppm) and the other three aromatic protons (4-H
’
, 5-H
’
, and 6-H
’
) 
resonated at 7.32 ppm (lit.
111
 7.34 ppm). The melting point of 14 was determined to 
be 115 – 117 oC which was consistent with the literature value (Lit.113 113-115 oC). 
In the HRMS, the molecular ion [MH
+
] was obtained at 238.0791 m/z which agreed 
with the calculated value of 238.0790 m/z. 
 
 
Scheme 2. 2: Mechanism showing intermediates involved in the formation of N-
benzylphthalimide from phthalic anhydride.
111
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Compound 14 was then subjected to an exhaustive Grignard reaction involving 
excess (6 equivalents) of the methyl magnesium iodide using the literature procedure 
described by Griffiths et al.
106
 The methyl magnesium iodide was prepared under 
inert conditions (argon atmosphere) by reacting activated magnesium turnings with 
methyl iodide in anhydrous diethyl ether. After concentrating the reaction mixture, a 
solution of compound 14 in anhydrous toluene was added and the reaction was 
heated at 110 
o
C for 3 hrs. Following filtration though basic alumina and 
recrystallisation from methanol, 2-benzyl-1,1,3,3-tetramethylisoindoline 15 was 
obtained as a white crystalline solid in modest yield (23%). 
Confirmation of the identity of this compound was achieved using 
1
H NMR 
spectroscopy, mass spectrometry and melting point determination. In the 
1
H NMR 
spectrum, the 12 hydrogens from the four methyl groups resonated at 1.32 ppm 
(lit.
114
 1.30 ppm) and the benzyl CH2 hydrogens appeared as a singlet at 4.01 ppm 
(lit.
114
 4.05 ppm). The 5 aromatic protons of the benzyl groups gave signals between 
7.23-7.33 ppm (lit.
114
 7.04 – 7.54 ppm). The obtained high resolution electrospray 
mass spectrum for compound 15 gave a mass of 266.1896 m/z ([M+H]
+
) which is 
consistent with the [M+H]
+
 molecular ion of the required molecular formula 
(C19H24N, 266.1903 m/z). 
 
The measured melting point of 62 – 64 oC was consistent with that reported in the 
literature(63 – 64 oC).114 The next step in the literature-based synthesis of iodo 
nitroxide 18 involved aromatic bromination. The treatment of compound 15 with 2.2 
equivalents of bromine in the presence of the lewis catalyst aluminium chloride in 
DCM gave the bromoamine intermediate 43. Final reduction of intermediate 43 with 
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hydrogen peroxide gave the desired 5-bromo-1,1,3,3-tetramethylisoindoline 16 as a 
white solid in good yield (74%). It was imperative that a large excess of bromine be 
avoided to restrict the occurrence of dibromination.  
 
The bromination reaction proceeds through the major intermediates shown in the 
reaction scheme 2.3.
115
 The first step involves bromination of the methylene carbon 
to form imine intermediate 41 which then undergoes electrophilic aromatic 
substitution with bromine to give 42. Subsequent loss of the benzylic group (as 
benzaldehyde) occurs by hydrolysis upon workup to afford the desired secondary 
amine 16. The presence of a small excess of bromine remaining in solution results in 
the formation of the bromoamine 43 which is converted to the free amine 16 by 
reduction with hydrogen peroxide, scheme 2.3. Compound 43 has been previously 
isolated and characterized and subsequent reduction with hydrogen peroxide gives 
compound 16.
115
 
Characterisation of the brominated analogue 16 was achieved through 
1
H NMR 
spectroscopy, mass spectrometry and melting point determination. The 
1
H NMR 
spectrum confirmed the loss of the benzyl group by the disappearance of both the 
methylene proton singlet at 4.01 ppm and the five aromatic proton signals of the 
benzyl group (multiplet signals at 7.23-7.33 ppm) The loss of symmetry from within 
the isoindoline aromatic system split the 12 methyl protons which originally 
resonated at as a singlet at 1.32 ppm for compound 15 into two signals. The 
appearance of the characteristic broad singlet at 1.66 ppm supported the presence of 
the secondary amine functionality. The 3 aromatic protons signals at 7.38 ppm (lit. 
7.34 ppm) for H-6, 7.26 ppm (lit. 7.23 ppm) for H-4 and 7.00 ppm for H-7 (lit. 6.98 
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ppm)
116
 were indicative of bromination on the 5-position of the aromatic ring. The 
obtained melting point of 57 – 59 oC was consistent with that previously reported in 
the literature (58 – 60 oC).117 
 
 
Scheme 2.3: Reaction pathway for the formation of 5-bromo-1,1,3,3-
tetramethylisoindoline.
111
 
 
Conversion of the bromoamine 16 into the more reactive iodoamine 17 was achieved 
through a standard halogen exchange reaction. Treatment of 16 with n-BuLi at -78
o
C 
in dry THF exchanged the bromine atom with lithium atom and deprotonated the 
amine and lithiated it to give 44 (Scheme 2.4). The reaction was performed at low 
temperature due to the inherent instability of the lithiated species. Subsequent 
addition of iodine led to the substitution of the lithium atom with iodine atom to 
produce intermediate species 45 which was reduced with H2O2 in the presence of a 
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catalytic amount of sodium bicarbonate to give 5-iodo-1,1,3,3-tetramethylisoindoline 
17 as white solid in 74% yield.  
 
Scheme 2.4: Reaction pathway for the formation of 5-iodo-1,1,3,3 
tetramethylisoindoline 17. 
 
As expected, the 
1
H NMR spectrum showed a slight downfield shift for the two 
aromatic protons (H4 and H6) adjacent to the carbon bearing the iodine atom. This 
observation results from the diminished shielding of electron of iodine compared to 
that of bromine.  
 
Formation of the desired nitroxide species, 5-iodo-1,1,3,3-tetramethylisoindolin-2-
yloyl 18, was achieved by oxidation of 17 with mCPBA at 0
o
C. After stirring for 20 
minutes at 0
o
C, the solution was warmed to room temperature and the product 
isolated. Unlike oxidation with H2O2 and sodium tungstate dihydrate which takes up 
to 3 days, this reaction is finished in under an hour. The mechanism first involves 
oxidation of the secondary amine into the corresponding hydroxylamine, which can 
then be oxidised into the nitroxide 18 with the assistance of molecular oxygen. The 
desired nitroxide 18 was isolated as a yellow solid in good yield of 84% yield after 
recrystallisation from ethanol.  
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The paramagnetic nature of the nitroxide moiety prevented the use of NMR 
spectroscopy for the characterisation of compound 18 as significant paramagnetic 
broadening is usually observed in both the 
1
H and 
13
C NMR spectra.
118
 Therefore 
characterisation was achieved using mass spectrometry and by melting point 
comparison with the literature. Using EI HRMS, the mass of the prepared compound 
matched that of the expected mass i.e. m/z ([M
+
]) expected was 316.0198 (found 
316.0204). The obtained melting point of 133 – 135 oC was consistent with that 
previously reported in the literature (132 - 135
o
C).
119
 
 
2.2 Synthesis of 5,6-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl (22). 
 
In order to prepare the required di-iodo compound 22, a new synthetic strategy had to 
be developed. As discussed previously, the usual method for introducing a single 
iodine atom onto the aromatic ring of the isoindoline structure involves lithiation of 
brominated isoindoline 16 followed by substitution of the lithium with an iodine 
atom (Scheme 2.4). However this method is not applicable for making di-iodo 
isoindoline derivatives since it generates the mono-lithiated and mono-brominated 
species 45 which  immediately decomposes into the very reactive benzyne 
intermediate 46 
120
 with the elimination of LiBr (Scheme 2.5). 
 
Scheme 2.5: Proposed mechanism for di-iodination of dibromo isoindoline 44. 
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The inherent reactivity of the benzyne intermediate may lead to other undesirable 
side reactions, for example formation of a dimer
121
 from two benzyne intermediate 
molecules (Scheme 2.6), which would effectively block subsequent iodination. 
 
 
Scheme 2.6: Mechanism of benzyne dimerisation. 
 
For these reasons, a new synthetic route to a di-iodinated isoindoline nitroxide was 
required. Bromine and chlorine substitution on aromatic rings is easily facilitated by 
lewis acids however due to its very unreactive nature, special techniques are required 
to make iodine reactive towards aromatic rings.
122,123
 Usually this is achieved by 
iodine oxidation into the strongly electrophilic iodinium ion (I
+
) with oxidising 
agents like sulphuric acid and nitric
121
 and methanesulfonic acid, N-
iodosuccinimide,
124
 sodium periodate (NaIO4), sodium iodate (NaIO3)
125
 and 
periodic acid (H5IO6).
126
 The iodination of the electron rich tetramethyl anthracene 
derivatives 46 and tetramethylfenestrindane 47 (Scheme 2.7) has been achieved 
using periodic acid, potassium iodide and sulphuric acid in 48% and 87% yields 
respectively.
126,127
 Both compounds possess structural similarity to the tetraalkyl 
isoindoline system, i.e. the two adjacent alkyl groups on each aromatic ring bear 
some structural similarity to the tetraalkyl isoindoline system.   
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Scheme 2. 7: Iodination of tetramethyl anthracene derivatives.
126,127
 
 
Thus with this structural similarity in mind, the same synthetic methodology was 
applied for the iodination of both the isoindoline and isoindoline nitroxide systems. 
 
Before aryl iodinations could be attempted, the isoindoline nitroxide 8 needed to be 
prepared. Using literature-based procedures,
114
 reductive debenzylation was 
undertaken on compound 15 by reacting it with hydrogen gas (at 60 psi) in the 
presence of 10% Pd/C catalyst in glacial acetic acid for 3 hours. Unlike non-protic 
solvents (eg THF and toluene) which lower catalysis rates, the reaction proceeds well 
in protic solvents such as acetic acid. Following work-up, pure 1,1,3,3-
tetramethylisoindoline 19 was isolated as a low melting white solid in high (90%) 
yield (Scheme 2.8).  
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Scheme 2. 8: Synthesis of 1,1,3,3-tetramethylisoindoline 19. 
 
In the 
1
H NMR spectrum of compound 19, the appearance of the amine proton signal 
at 1.78 ppm was a strong indication of success of the debenzylation reaction. The 
disappearance of the aromatic protons and benzyl CH2 protons provided more 
evidence for the success of the reaction. The chemical shifts of the aromatic protons 
of compound 19 compared well with previously published data H- 4 and H-7 
resonated at 7.15 ppm [lit.
116
 7.12 ppm] and H-5 and H-6 appeared at 7.26 ppm 
[lit.
116
 7.24ppm]. The obtained melting point of 37 – 39 oC was consistent with that 
previously reported in the literature (36 – 38 oC).114 
 
Oxidation of 19 with mCPBA in DCM gave 1,1,3,3-tetramethylisoindolin-2-yloxyl 8 
after stirring at room temperature for 1 hr (Scheme 2.9). Nitroxide 8 was obtained in 
a high yield (80%). The obtained melting point of 129 – 131 oC was consistent with 
that previously reported in the literature (128 – 131 oC).114 
 
Scheme 2.9: Synthesis of 1,1,3,3-tetramethylisoindolin-2-yloyl 8. 
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With the isoindoline nitroxide 8 in hand, aryl iodination could be attempted using 
periodic acid, potassium iodide and sulfuric acid. The mechanism of this reaction 
(Equations 15 - 17) involves the reaction of periodic acid with hydroiodic acid 
(formed from the reaction of potassium iodide with H2SO4) and H2SO4 to produce 
IOSO3H, which is the I
+
 containing iodinating agent.
128
 Note in equations 16 and 17 
that for every 4 moles of I
+
 produced, 3 moles of KI and 1 mole of periodic acid are 
consumed. 
 
 
 
Once I
+
 is generated, the reaction proceeds normally through electrophilic aromatic 
substitution
129
 (see reaction scheme 2.10). 
 
Scheme 2. 10: Proposed mechanism of the reaction for conversion of 18 to 22.  
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Initial attack on the iodinium ion by the aromatic ring forms carbocation intermediate 
48, which is then deprotonated to give the mono-iodinated product 18. The cycle is 
repeated for the formation of 22 with iodine substitution occurring on the adjacent 
carbon atom (C6). Under this oxidative I
+
 formation condition, there is potential for 
oxidation of TMIO 20 to the corresponding nitrone. However, upon exposure to air, 
it would reform the nitroxide. 
 
Using these conditions, the iodinium ion was generated at 0 
o
C by dissolving 
periodic acid in 98% H2SO4. To this was added potassium iodide and nitroxide 8 
(Scheme 2.11). The reaction was carried out using various equivalents of I
+
 ranging 
from 0.70 to 5.00 (Table 2.1). 
 
 
Scheme 2. 11: Synthesis of 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl 18 and 
5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22. 
 
Using one equivalent of I
+
, the reaction was carried out for 3 hours, after which time 
no starting material was observed by TLC. Analysis of the product by reversed phase 
analytical HPLC revealed the presence of the mono-iodinated product 18, di-
iodinated product 22 and unreacted starting material 20 in a ratio of 18:11:1 
respectively. Following these results, iodination reactions were performed with less 
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than one equivalent of I
+
 to determine the optimal equivalents of I
+
 required to 
maximise the yield of the mono-iodo product 18 and minimise the formation of di-
iodo product 22. It was established that 0.70 I
+ 
equivalent generates the maximum 
proportion of the mono-iodinated derivative 18 compared to the di-iodinated 
counterpart 22 and the unreacted starting material 20, producing each of them in a 
ratio of 14:1:5 respectively (Figure 2.1). With 2.2 equivalents of I
+
, compound 22 
and 18 were observed in ratio of 10:1 respectively and all the starting material 20 
was consumed. Increasing the I
+
 equivalents to 3.6, led to complete conversion of 20 
to 22 and no compound 18 was detected (Table 2.1 and Figure 2.2). The use of 5.0 
equivalents of I
+ 
did not alter the reaction outcome significantly with analytical 
HPLC indicating 96% of 22 in the crude compound. Following chromatography (5 I
+
 
equivalent reaction), di-iodo product 22 was isolated using column chromatography 
in a yield of 82%. 
 
 
Figure 2. 1:   Analytical C18 HPLC chromatogram (eluent: 80% MeOH in H2O) of 
crude 5-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl formed after treatment of 
nitroxide 20 with 0.7 equivalents of I
+
.    
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Table 2.1:   The ratio of products formed by HPLC from the reaction of nitroxide 20 
with various equivalents of I
+
. 
 
 
I
+ 
equiv. 
Product ratio by HPLC 
   
0.70 23 70 5 
0.85 18 67 12 
1.00 3 54 32 
2.20 0 8 83 
3.60 0 0 95 
5.00 0 0 96 
 
 
Figure 2.2: Analytical C18 HPLC chromatogram (eluent: 80% MeOH in H2O) of 
crude 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22 formed after the treatment 
of nitroxide 20 with 5 equivalents of I
+
. 
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Compound 18 was identified using mass spectrometry and melting point 
determination. EI
+
 MS gave a molecular ion [M
+
] at 316.1 m/z which was in 
agreement with the predicted mass of 316.0198 m/z. Furthermore, the melting point 
was consistent with the range reported in the literature i.e. 129 – 131oC (128 – 131 
o
C lit.
114
).   
 
Characterisation of 22 was achieved using mass spectrometry, elemental analysis, X-
ray diffraction and melting point determination. Using EI HRMS, the obtained mass 
(i.e. m/z [M
+
] = 441.9159] corresponded to the expected value of 441.9165 m/z. In 
the elemental analysis, the obtained composition of 32.57% for carbon, 3.09% for 
hydrogen and 3.12% for nitrogen was within a ±5% error limit from the expected 
composition values of 32.60% for carbon, 3.19% for hydrogen and 3.17% for 
nitrogen. Slow evaporation of a DCM solution of 22 gave crystals suitable for single-
crystal X-ray analysis (Figure 2.3). The unit cell displays similar dimension and 
crystal structure to that of 5,6-dibromo-1,1,3,3-tetramethylisoin-2-yloxyl and 5,6-
cyano-1,1,3,3-tetramethylisoin-2-yloxyl.
115,130
 Half of the molecules of the 
asymmetric unit cells lie on the crystallographic two-fold axis coincident with the 
nitroxide N(1)-O(1) bond. The nitroxide N-O bond length of 1.272 (4)A
o
 is in 
agreement with that for 5 membered isoindoline type nitroxides.
117
 More 
importantly, the X-ray structure confirms that the two iodine atoms are attached to 
carbon atoms number 5 and 6 instead of carbon atoms 4 and 7 of isoindoline 
aromatic ring (Figure 2.3). 
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Figure 2.3:    X-ray structure of 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloxyl 
(22). 
 
The formation of the di-iodinated derivative 22 when less than one equivalent of I
+ 
suggests that the aromatic ring is not deactivated towards a second iodination once 
mono-iodination has occurred. Substitution of an iodine atom onto an unsubstituted 
aromatic benzene ring normally weakly deactivates it towards further substitution. 
Due to its electronegativity, iodine withdraws electrons inductively from the 
aromatic ring and at the same time one of the lone pairs on iodine has the tendency to 
conjugate (scheme 2.12) with the aromatic ring; however the inductive effect is 
slightly stronger than the electron donating effect hence the weak deactivation of the 
ring.
121
 Despite this deactivating tendency of iodine towards aromatic rings, 
monoiodination of TMIO 20 (to form compound 18) appears to make compound 18 
even more reactive towards I
+
 forming compound 22. It is postulated that the I
+ 
species is so reactive that the relative inertness/deactivated nature of the aromatic 
ring of 18 is irrelevant.   
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Scheme 2. 12: Electron delocalisation on a mono-iodinated aromatic ring. 
 
With the desired mono- and di-iodo nitroxides in hand, exploration of the new 
iodination methodology was also undertaken on the isoindoline 19. Compounds 17 
and 21 were synthesised following the same procedure used to prepare compounds 
18 and 22 respectively. Periodic acid was dissolved in 98% H2SO4 at 0 
o
C followed 
by the addition of potassium iodide and after stirring for 15 minutes, 1,1,3,3-
tetramethylisoindoline 19 was added. The reaction was then stirred at room 
temperature for 3 hours (Scheme 2.13). 
 
Scheme 2. 13: Synthesis of compounds 17 and 21. 
 
The outcome of the reaction was investigated using various equivalents of I
+
 (Table 
3). 1.1 Equivalents of I
+
 gave the mono-iodinated TMI 17 and the di-iodinated 
derivative 21 in a ratio of 2:1 respectively, following analysis by 
1
H NMR 
spectroscopy (Figure 2.4). Increasing the equivalents of I
+
 to 2.2 led to the 
production of 17 and 21 in a ratio of 1:2 respectively. When 2.8 and 5.0 respective 
equivalents of I
+
 were employed, in each case di-iodo product 21 was exclusively 
observed, following analysis with 
1
H NMR spectroscopy (Figure 2.5). Purification 
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achieved by silica chromatography in DCM/diethyl ether gave pure 21 in good yield 
(70%).  
Table 3:  Ratio of products formed (by 
1
H NMR spectroscopy) when amine 19 was 
treated with various equivalents of I
+
.  
 
 
I
+ 
equiv. 
 
 
Product ratio by 
1
H NMR spectroscopy 
   
1.10 0 69 31 
2.20 0 39 61 
2.80 0 0 100 
5.00 0 0 100 
 
NH
NH
I
I
H
H
H
H
I
a
d
b
c
b
c
d
a
7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5
1.000.910.900.87
21
17
H
a
 
 
Figure 2. 4: 
1
H NMR spectrum (aromatic region, 400 MHz, CDCl3) of the crude 
product obtained following the addition of 1.1 equivalents of I
+
 to TMI 19. 
 
Chemical shift (ppm) 
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Characterisation of 21 was achieved using 
1
H (Figure 2.5) and 
13
C NMR 
spectroscopy, elemental analysis and mass spectrometry. In the 
1
H NMR spectrum, 
the 2 aromatic protons resonated as a singlet at 7.64 ppm, the amine proton appeared 
as a broad singlet at 1.60 ppm and the 12 protons of the 4 methyl groups appeared as 
a singlet at 1.44 ppm. In the 
13
C NMR spectrum, the 6 aromatic protons gave signals 
between 106 ppm and 152 ppm, quaternary carbons 1 and 3 appeared at 62 ppm and 
the 4 methyl group carbons were found at 32 ppm. Elementary analysis for carbon 
33.54%, hydrogen 3.46% and nitrogen 3.18% agreed with the predicted values of 
33.75%, 3.54% and 3.28% respectively within the accepted ±5% error limit. More 
evidence for the identity of 21 came from ESI mass spectrometry with the observed 
molecular ion [M+H]
+
 at 427.9400 m/z consistent with the expected value of  
427.9294 m/z. 
NH
CH3
H3C
CH3H3C
I
I
b
cH
a
c
b
a
21
c
c
c
H
a
 
Figure 2. 5:   
1
H NMR spectrum (400 MHz, CDCl3) of compound 21 following 
purification by column chromatography. 
 
Chemical shift (ppm) 
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As mentioned previously, bromination of TMI 19 gives the bromoamine derivative 
51 which then requires an additional reduction step using H2O2 to obtain the 
secondary amine 16 (Scheme 2.14). This extra step is eliminated in the new method 
of iodination as the reaction is carried in an acidic environment. Under these 
conditions, the amine group will be protonated giving it a positive charge and thus 
preventing the iodinium ion from attacking it. 
 
Scheme 2. 14: Suggested reason for the lack of formation of iodoamine 52. 
 
2.3. Synthesis of 5-iodo-1,1,3,3-tetraethylisoindolin-2-yloxyl (28) and 
5,6-diido-1,1,3,3-tetraethylisoindolin-2-yloxyl (29). 
 
Following the development of this new aryl iodination methodology, its application 
to tetraethyl-based isoindoline and isoindoline nitroxide based systems was next 
investigated. Previous work in this area has shown that attempted bromination on the 
aromatic ring of the tetraethyl system using bromine and an AlCl3 catalyst gave a 
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poor yield (31%) of the mono bromo product and a large amount of decomposition 
(presumably from ring-opened reactions).
108
 Thus, if the new methodology could be 
applied to the tetraethyl isoindoline system, it would be very useful.  
 
Before the aryl iodinations were attempted, the tetraethyl based starting materials 
needed to be prepared. Synthesis of 1,1,3,3-tetraethylisoindoline 24 was carried out 
by debenzylation of 2-benzyl-1,1,3,3-tetraethylisoindoline 23 using hydrogen gas at 
60 psi in glacial acetic acid with 10% Pd/C catalyst for 4.5 hours (scheme 2.15). 
Following work-up, the desired compound 24 was isolated as a colourless oil in 93% 
yield. The 
1
H NMR spectrum of the obtained product showed that the benzyl group 
has disappeared and the characteristic amine proton signal had appeared at 1.28 ppm. 
The four aromatic hydrogens resonated in the range of 7.09 – 7.26 ppm. The eight 
CH2 protons appeared at 1.70 ppm and the four CH3 protons resonated at 0.90 ppm.  
 
Scheme 2. 15: Preparation of 1,1,3,3-tetraethylisoindoline 24. 
 
Conversion of the secondary amine 24 into the corresponding nitroxide 25 (scheme 
2.16) was achieved using a standard mCPBA oxidation as discussed previously for 
the preparation of compound 20. The desired nitroxide compound was obtained in a 
good yield of 75% after purification by silica column chromatography. EI HRMS 
showed a molecular ion at m/z [M
+
] = 246.1858 which is identical to the expected 
Chapter two 
70 
 
value of 246.1858 m/z. The compound was shown to be 96% pure by analytical 
HPLC (see appendix for the chromatogram).  
 
Scheme 2. 16: Synthesis of 1,1,3,3-tetraethylisoindolin-2-yloxyl 25. 
 
5,6-Diiodo-1,1,3,3-tetraethylisoindolin-2-yloyl 29 (scheme 2.17) was generated 
following the same optimized procedure used to synthesise compound 22 employing 
4 equivalents of I
+
. Purification was performed using silica chromatography to give 
product 29 in a 37% yield (Figure 2.6). Interestingly, nitrones 30 and 31 were also 
formed in yields of 8.4% and 12.7% respectively.  
 
Scheme 2. 17: Synthesis of 5,6-diido-1,1,3,3-tetraethylisoindolin-2-yloxyl 29. 
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Figure 2. 6: Analytical C18 HPLC chromatogram (95% methanol in water) for 
purified compound 29. 
 
The formation of nitrones begins with the oxidation of TEIO 25 into the 
oxoammoniun cation 53 (scheme 2.18) which in turn loses ethylene to give 
intermediate 54. Final loss of a proton gives the nitrone 55 (Scheme 2.17).
131
 Nitrone 
formation was not observed in the previously described iodination of TMIO 8 as it is 
more resistant (reduction potential, E
r
 = 0.77V)
132
 towards oxidation than TEIO (E
r
 = 
0.729V)
132
 and the tetramethyl system cannot form intermediate 54 by the loss of 
ethene. 
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Scheme 2. 18: General mechanism for nitrone 55 formation. 
The nitrones 30 and 31 were characterized by 
1
H and 
13
C NMR spectroscopy, mass 
spectrometry and analytical HPLC. The asymmetric nature of nitrone 30 means that 
the aromatic protons on C-4 and C-7 have different chemical shifts in the 
1
H
 
NMR 
spectrum. Due to its proximity to the electron rich C-3, the proton on C-4 resonated 
at 7.85 ppm as a singlet whereas the proton on C-7 appeared slightly upfield at 7.70 
ppm. The ethyl group on C-3 gave a triplet at 1.26ppm and the methylene group 
came as a quartet at 2.81 ppm. The two ethyl groups on C-1 resonated at 0.44 ppm as 
triplet and multiplets at 2.18 ppm and 1.87 ppm respectively. In the 
13
C NMR 
spectrum, six aromatic carbons signals were observed in the range of 106 to 146 ppm 
with the iodine bearing carbons C-5 and C-6 giving signals at 146 ppm and 142 ppm 
respectively.. The ESI HRMS of nitrone 30, gave a molecular ion peak (i.e. m/z 
[M+H]
+
=469.9480) which corresponded to the predicted value of 469.9400 m/z. 
Analytical HPLC of nitrone 30 showed predominantly a single peak (Figure 2.7).  
Nitrone 31 was characterized by NMR spectroscopy, mass spectrometry and HPLC. 
However attempts to assign individual peaks were not successful due to the presence 
of regioisomers within the mixture. In the ESI HRMS, the obtained molecule ion for 
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[M+H]
+
 at 344.0525 m/z matched with the predicted value of 344.0433 m/z. 
Analytical HPLC in methanol/water (95/5) gave a single peak (Figure 2.8). 
 
Figure 2. 7: Analytical C18 HPLC chromatogram (95% methanol in water) of pure 
compound 30. 
 
 
Figure 2. 8: : Analytical C18 HPLC chromatogram (95% methanol in water) of 
compound 31. 
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2.4. Synthesis of 5,6-diiodo-1,1,3,3-tetraethylisoindoline (26) and 5-
iodo-1,1,3,3-tetraethylisoindoline (27). 
 
5,6-Diiodo-1,1,3,3-tetraethylisoindoline 27 was prepared following the same 
procedure used to make compound 21 (4 equivalents of I
+
) in 80% yield. Excess 
iodine was removed by washing with sodium thiosulphate and purification by silica 
gel chromatography gave the desired compound 27 as a white solid (Scheme 2.19). 
 
Scheme 2. 19: Preparation of 5,6-diiodo-1,1,3,3-tetraethylisoindoline (26) and 5-
iodo-1,1,3,3-tetraethylisoindoline (27). 
 
Derivative 27 was characterised by NMR spectroscopy and mass spectrometry. 
Using 
1
H NMR spectroscopy, the 2 aromatic protons resonated at 7.58 ppm as a 
singlet. The signal for the 8 methylene protons and the single amine proton 
overlapped with resonances between 1.55 ppm and 1.55 ppm. The 12 protons of the 
4 methyl groups were found at 0.88 ppm (Figure 2.9). In the 
13
C NMR spectrum, the 
6 aromatic carbons came in the range of 105 ppm to 150 ppm, C1 and C3 were found 
at 68 ppm, the 4 methylene carbons at 33 ppm and the 4 methyl carbons are at 8 
ppm. The molecular ion of 484.0022 m/z obtained in the ESI mass spectrometry 
matched the calculated mass for an [M+H]
+
 ion (m/z calcd. 483.9920).  
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Figure 2. 9:    
1
H NMR spectrum (400 MHz, CDCl3) for compound 27.  
 
The synthesis of 5-iodo-1,1,3,3-tetraethylisoindoline 26 was attempted with 0.7 
equivalents of I
+ 
and after work up, analysis of the product by 
1
H
 
NMR spectroscopy 
and HPLC indicated the presence of starting material 24, mono-iodo product 26 and 
di-iodo product 27 in a ratio of 1:6:1. Attempts to separate the mixture using silica 
gel column chromatography and Reversed Phase Medium Pressure Liquid 
Chromatography (MPLC) were not successful. 
 
The mixture was therefore oxidised with mCPBA into the corresponding nitroxides. 
Separation was then achieved by running the mixture through a silica column using 
Chemical shift (ppm) 
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chloroform as the solvent to obtain 48% of 28, 28% of 25 and only trace amount of 
29. Compound 28 was characterised by mass spectrometry and analytical HPLC. The 
parent peak in the HRMS for [M+H]
+
 at344.0525 m/z matched the predicted value of 
344.0433 m/z. Analytical HPLC in methanol/water (95/5) (see appendix) gave a 
single peak eluting at 2.97 minutes. 
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3.0. SYNTHESIS OF RESVERATROL-NITROXIDE 
ANALOGUES 
With the iodinated nitroxide precursors now in hand, the target compounds 12 and 13 
should now be accessible using the palladium-catalysed Heck reaction from the 
corresponding styrene derivative. 
 
3.1. The Heck Reaction 
The Heck reaction (Scheme 3.1), developed independently by Mizoroki and Heck, 
involves vinylation of aryl/vinyl halides (or triflates) using a palladium complex 
catalyst with or without ligands.
133
 Mild reaction conditions allow the use of 
inexpensive reagents with low toxicity but the reaction is also highly chemoselective 
which makes it a very attractive synthetic route.
134
  
 
 
 
Scheme 3. 1: General equation for the Heck reaction. 
 
Before entering the catalytic cycle (Scheme 3.2), palladium (II) is reduced to 
palladium (0) (this process is facilitated by the phosphine in a phosphine assisted 
catalytic cycle and other nucleophiles that facilitate this step include hydroxides, 
alkoxides, and water and acetate ions). Once the palladium (0) ligand complex 
(species A) is formed, the catalytic cycle begins by oxidative insertion of the 
complex into the bond joining the aryl/vinyl to the halide or triflate bond to form the 
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palladium (II) complex species B (this step is termed oxidative addition). In the next 
step, the unsaturated system is inserted into the Pd-R bond of species B to form the 
palladium (II) complex species C (insertion step). The insertion is stereoselective and 
always occurs in the syn manner. Then β-elimination of hydride from species C leads 
to release of the desired alkene product from the cycle leaving the palladium (II) 
complex species D. This complex then undergoes reductive elimination to regenerate 
the palladium (0) species A and the catalytic cycle continues. Often polar solvents 
like acetonitrile, N,N-dimethylformamide or methanol are used; reaction 
temperatures range between 0 to 250 
o
C.
135
 The substitution of the hydrogen 
preferentially occurs at the carbon centre with the larger number of hydrogen atoms. 
The reaction occurs in a fashion where Pd adds to the more electron rich carbon, 
electron rich alkenes are generally not used
136
 as regioselectivity is often poor. Thus 
alkenes with electron withdrawing groups are preferred.
75,136
 
Pdo or PdII
Pdo
L
A
PdII
L L
L
R X
PdII
L L
XR
H
PdII
L L
XH
RX
R
Base
Base HX
B
C
D
 
Scheme 3. 2: Schematic mechanism of the Heck reaction. 
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3.2. Synthesis of (E)-5-(2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)vinyl)-1,3-phenylene diol (12). 
 
Resveratrol nitroxide 12 could be prepared by palladium catalysed Heck coupling of 
3,5-diacetoxy styrene 34 with iodo-nitroxide 18 followed by subsequent base 
catalysed deacetylation. The starting material 34 was prepared using a two step 
process. 3,5-Dihydroxy styrene 33 was prepared using a procedure reported in the 
literature
109
 employing the Wittig reaction. The Wittig reaction has been reported to 
proceed more rapidly in DMSO than in customary solvents like ether, often with 
superior yields of olefins.
137
 Here the Wittig reagent (ylide) 54 was prepared by 
heating DMSO with NaH at 70 
o
C to inevitably generate the basic methylsulfinyl 
carbanion 53 which then acted as a base to deprotonate the methyl group of 
methyltriphenyphosphonium bromide to form the methylenetriphenylphosphorane 
54. 3,5-Dihydroxybenzylaldhyde 32 then reacted with the ylide 54 to afford the 
desired 3,5-dihydroxy styrene 33 via intermediate 55 (Scheme 3.5). The reaction was 
quenched with an ice/diethyl ether mixture and following initial extraction with 
diethyl ether and subsequent purification with silica gel column chromatography, a 
50% yield of 3,5-dihydroxy styrene 33 was obtained. This was in disagreement with 
the literature reported yield of 98% .
109
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Scheme 3. 3: The reaction mechanism for the synthesis of compound 33. 
 
As the reaction occurred in a basic environment, it is likely that some of the phenolic 
groups of the target compound 33 could be deprotonated, thereby conferring a 
negative charge on them. Therefore, it was presumed that the diminished yield 
recorded was due to incomplete extraction of compound 33 as charged compounds 
have poor solubility in organic solvents. To ascertain this, the reaction was repeated 
with a modified work-up which involved acidification of the reaction mixture with 
5M HCl before the extraction step. As expected this time, the isolated yield of 33 
greatly improved to 91% after purification by silica column chromatography.  
 
 
Scheme 3. 4:  Synthesis of compound 33. 
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Characterization of compound 33 was achieved using 
1
H NMR spectroscopy and 
mass spectrometry. In the 
1
H
 
NMR spectrum, two aromatic protons resonated as a 
singlet at 6.30 ppm (lit.
138
 6.46 ppm) whilst the other aromatic proton appeared as a 
singlet at 6.14 ppm (lit.
138
 6.25 ppm). The ethylene proton appeared as a doublet of 
doublets at 6.53 ppm with coupling constants of 11 Hz (cis) and 17.2 Hz (trans) 
respectively (lit.
138
 6.56 ppm, Jcis=10.8 Hz, Jtrans=17.7 Hz). One of the terminal 
alkene protons appeared as a doublet at 5.62 ppm with a coupling constant of 17.6 
Hz (lit.
138
 5.67 ppm, J(cis)=17.7 Hz). The ethylene trans hydrogen resonated as a 
double at 5.15 ppm with a coupling constant of 11.2 Hz (lit.
138
 5.23 ppm, J(trans)=10.8 
Hz). Low resolution MS (EI) gave the expected molecular ion (M
+
) at 136 m/z with 
100% peak intensity. 
 
3,5-Diacetoxy styrene 34 was obtained by acetylation of styrene 33 using acetic 
anhydride in the presence of pyridine and DMAP in DCM at room temperature 
overnight (Scheme 3.6). After work up and purification with silica gel column 
chromatography (50% DCM in chloroform) the acetylated target 34 was obtained as 
colourless oil in 84% yield. 
 
Scheme 3. 5: Acetylation of compound 33 to give 34. 
 
Characterisation of compound 34 was achieved using 
1
H
 
NMR spectroscopy. The 
appearance of the six methyl protons at 2.31 ppm (lit.
138
 2.30 ppm) confirmed the 
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success of the acetylation. Two aromatic protons appeared at 7.04 ppm (lit.
138
 7.04 
ppm) and the other aromatic proton was present at 6.84 ppm (lit.
138
 6.84 ppm). The 
phenyl ethylene proton appeared as a doublet at 6.67 ppm (lit.
138
 6.66 ppm) and the 
cis and trans protons appeared at 5.34 ppm (lit.
138
 5.33 ppm) and 5.76 ppm (lit.
139
 
5.75 ppm) respectively.  
 
With the protected styrene in hand, the Pd-catalysed Heck coupling with iodinated 
nitroxides could now be attempted. Guiso et. al. have previously used the Heck 
reaction to synthesise resveratrol with 1% Pd(OAc)2 catalyst (based on moles of the 
aryl halide), 6.2% triphenylphosphine ligand, triethylamine as base and acetonitrile 
solvent to obtain resveratrol in a 70% yield.
138
 In this project, the synthesis of the 
resveratrol analogue 35 was attempted using the same reaction conditions (Table 4, 
Entry 1) and the reaction progress was monitored by TLC. After the disappearance of 
aryl halide 18, the reaction was quenched by the addition of ice followed by 
acidification with 1 M HCl. The crude compound was extracted with diethyl ether. 
Purification with silica gel column chromatography using 90% DCM in diethyl ether 
gave a 22.5% isolated yield of target compound 35, a 5% isolated yield of 12 and a 
negligible amount of the mono acetylated derivative (<1%). Traces of various other 
compounds were also identified on the TLC plate (6 spots) but these were difficult to 
separate and present in quantities insufficient for characterization purpose.  
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Table 4: Various reactions conditions employed for the Heck of styrene 34 with 
iodo-nitroxide 18. 
Entry 
Pd(OAc)2 
(mol%) 
PPh3 
(mol%) 
Solvent Base Temp 
(
o
C) 
Reaction 
time (hrs) 
Isolated 
yield of 
product 
35 
1 1 6.4 CH3CN TEA 85 19 22.5 
2 10 20 DMF K2CO3 80 46 29.2 
3 5 10 DMF K2CO3 120 72 - 
 
 
Scheme 3. 6: Heck synthesis of compound 12. Reagents and conditions: Pd(OAc)2, 
dry DMF, dry K2CO3, 120 
o
C, 72 hrs (iv) K2CO3, THF/H2O/MeOH. 
 
Due to the low yield of the desired product 35, the reaction was repeated using 10 
mol% palladium catalyst and 20 mol% triphenylphosphine in DMF at 80
o
C (Table 4, 
Entry 2). These conditions were earlier used by Colwell et. al. to make the nitroxide 
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containing stilbene derivative 36.
140
 The Heck reaction is known to proceed well 
with electron deficient alkenes. Despite the 2 electron donating tertiary butyl group 
on the starting alkene, a relatively good yield (71%) of 36 was obtained using these 
conditions. Therefore it was hoped that these condition would furnish compound 35 
in a significantly higher yield. Disappointingly, under these conditions, 35 was 
isolated in only a 29.2% yield in combination with a small proportion (8.3%) of 
partially deacetylated and fully deacetylated (12) compounds. 
 
The reaction was then carried out with 5 mol% Pd(OAc)2, 10 mol% PPh3 and 
anhydrous potassium carbonate as base in anhydrous DMF at 120
o
C for 72 hours. 
These reaction conditions were chosen due to previous observation that for Heck 
synthesis of stilbene derivatives, 10 mol% or more of the catalyst causes a decrease 
in catalytic activity.
75
 After purification of the crude product by silica gel column 
chromatography, none of the desired compound 35 was isolated. Instead compound 
12 (36% isolated yield) and compound 37 (25% isolated yield) were obtained. The 
mechanism of formation of 37 is currently unclear but the acetyl group most 
probably arises from the catalyst (Pd(OAc)2) or migrates from the phenolic group. In 
any case, it is presumed that the Pd facilitates the acetylation of the nitroxide as the 
acetylation of TEIO 25 has previously been achieved through Pd catalysis using 
acetyl chloride.
108
  Another possible explanation is that TMIO 8 (reduction potential 
1.045 V
119
) could oxidize the palladium (reduction potential 0.951 V
141
) into 
palladium (II) thereby removing the catalytically active portion of the palladium 
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from catalytic cycle and in the process forming compound 38 which can then be 
acylated to form compound 39 (Scheme 3.7). 
 
Scheme 3. 7:  General equation for oxidation of palladium (0) and acylation of 
TMIO 8 
 
Finally treatment of compound 35 with potassium carbonate in a mixture of 
THF/H2O/MeOH was used to remove the acetyl protecting groups. Purification of 
the resulting product by silica gel column chromatography gave the desired 
resveratrol nitroxide 12 as brown solid in high yield of 82%. Crystals of this 
compound was obtained by slow evaporation of an ethyl acetate/cyclohexane 
solution.  
The target compound 35 was characterised by mass spectrometry, elemental analysis 
and HPLC. In the EI HRMS, the parent peak [M
+
] at 324.1604 m/z corresponded 
with the predicted value of 324.1600. Elemental analysis for carbon 73.53%, 
hydrogen 6.76% and nitrogen 4.18% agreed with the predicted values of 74.05%, 
6.84% and 4.32% respectively within the allowable ±5% error limit. Analysis by 
analytical HPLC showed a single peak with ≥ 98% purity. 
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The use of the di-iodo nitroxide 22 in the Heck reaction with 3,5-diacetoxy styrene 
34 was also explored. Using the best conditions described above, 2 moles of 3,5-
diacetoxy styrene 34 was reacted under Heck conditions with 5,6-diido-1,1,3,3-
tetraethylisoindolin-2-yloyl 22. Purification of the resulting crude compound using 
silica gel column chromatography and analysis of the fractions with ESI HRMS 
revealed monoacetylated derivative with predicted parent molecular ion 
[M+2H]
+
=502.2073 m/z (found 502.2235 m/z), diacetylated derivative with expected 
molecular ion [M+H]
+
=544.2179 m/z (found 544.2343 m/z) and triacetylated 
derivative with predicted molecular ion [M+H]
+
=586.2284 m/z (found 586.2450 
m/z). Acetyl protecting group are known to be labile in basic condition
142
 therefore 
the observed deacetylation is not a surprise as the reaction is carried in basic 
environment. These compounds were combined and treated overnight with 2 M 
sodium hydroxide. Silica gel column chromatography in ethyl acetate/hexane (6/4) 
gave the desired compound 13 in an unoptimised yield of 1.6%.  Characterisation 
was achieved using EI HRMS with the mass of the parent molecular ion [M
+
] at 
458.1967 m/z consistent with the predicted value of 458.1967 m/z. Analytical HPLC 
indicated 94% purity (see figure A.11 in the appendix). Further work to optimize this 
reaction is required but the ability to isolate the desired di-coupled product 13 shows 
promise.  
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Scheme 3. 8: Reagents and conditions: (i) Pd(OAc)2, dry DMF, dry K2CO3, 120 
o
C, 
24 hrs (ii) 2 M NaOH, RT, O/N. 
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4.0. BIOLOGICAL EVALUATION OF RESVERATROL-
NITROXIDE ANALGUES 
 
With one of the resveratrol-nitroxide target molecules 12 in hand in sufficient 
quantities, potential use as a treatment for hypertension could be explored. 
 
4.1. Biological Testing: Effects of Resveratrol-Nitroxide (12) on DOCA-
Salt Hypertensive Rat Models. 
 
Rats with one of their kidneys surgically removed develop hypertension with 
characteristics similar to that seen in humans when they are administered the 
synthetic mineralocorticoid derivative deoxycorticosterone acetate (DOCA) in 
combination with sodium chloride.
143
 Cardiac hypertrophy, which is commonly 
associated with hypertension, is very pronounced in both the right and left ventricles 
of the hearts of DOCA-salt hypertensive rat models. There is also decreased 
circulating plasma rennin concentration in DOCA-salt hypertensive rats due to 
depression of the rennin angiotensin system which normally induces aldosterone 
secretion. Normally, elevation of aldosterone level in the blood leads to an increase 
in the reabsorption of sodium ions and water from kidney causing an elevation in 
blood pressure.
144
 Thus, the possibility of the blood pressure of the DOCA-salt 
hypertensive rats being altered by aldosterone is minimized. Due to these attributes, 
DOCA-salt hypertensive rats are attractive biological models for studies of 
hypertension. 
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As mentioned earlier, one of the main objectives of this project was to synthesise 
nitroxide coupled analogues of resveratrol (resveratrol-nitroxide) for treatment of 
cardiovascular diseases. Keeping this objective in view, the effects of oral 
administrations of resveratrol-nitroxide 12 in the DOCA-salt hypertensive male 
wistar rats were studied over a period of 4 weeks in collaboration with Professor 
Lindsay Brown’s research group at the University of Southern Queensland.  
 
The specimen rats were classified into three separate groups. The first group (control, 
labeled as UNX) consisted of rats with a single kidney removed. None of compound 
12 was administered to this group. The second group, labelled DOCA, were DOCA-
salt hypertensive rats which did not receive compound 12. The third group, referred 
to as DOCA+NitroResveratrol, were DOCA-salt hypertensive rats which were orally 
administered resveratrol-nitroxide 12 (1 mg/kg of rat suspended in oil) daily for 4 
weeks. 
In previous experiments carried out with DOCA-salt hypertensive rats using the 
parent compound resveratrol 1 (Figure 4.1A
103,145
), the DOCA rats failed to 
significantly gain weight.  
However, unlike in the previous experiment, treatment of the DOCA salt 
hypertensive rats with resveratrol-nitroxide 12 led to slight gain of weight (Figure 
4.1B). Thus this suggests that resveratrol-nitroxide 12 may improve the food intake 
of the sickly hypertensive DOCA-salt rats but additional experiments are needed to 
confirm this finding. 
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Figure 4. 1:   Daily body weight measurements for UNX, DOCA, DOCA+ 
NitroResveratrol, UNX+ resveratrol and DOCA+ resveratrol. A = Resveratrol
103
 and 
B = Resveratrol-Nitroxide 
 
The DOCA-salt hypertensive rats displayed increased water intake compared to the 
UNX rats which is in agreement with previous observations
103
 (Figure 4.2). 
However, unlike in previous experiments in which resveratrol failed to alter water 
intake in the DOC-salt hypertensive rats, resveratrol-nitroxide 12 reduced water 
intake of the DOCA-salt rats with respect to the UNX rats by nearly half. 
 
A 
B 
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Figure 4. 2:   Daily water intake measurements for UNX, DOCA, DOCA+ 
NitroResveratrol, UNX+ resveratrol and DOCA+ resveratrol. A= resveratrol
103
 and 
B= resveratrol nitroxide. 
 
 
As expected, the DOCA-salt hypertensive rats had elevated systolic blood pressure 
compared to the UNX rats (Figure 4.3). Administration of resveratrol-nitroxide 12 
attenuated the blood pressure of the DOCA-salt rats bringing it down to the original 
A 
B 
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blood pressure of the UNX rats. The reduction of the blood pressure may be 
attributed to the decrease in water absorption mentioned earlier however whether this 
is the case will be investigated in the subsequent experiments. 
 
Figure 4. 3:   Systolic blood pressure measured using the tail cuff method for UNX, 
DOCA, and DOCA+NitroResveratrol. 
 
Treatment of the isolated thoracic aortic rings of the various groups with 
noradrenaline (NA) induced higher contractile response in the DOCA-salt 
hypertensive rats compared to the UNX rats (Figure 4.4 (A)). Noradrenaline is a 
neurotransmitter that cause an increase in the rate of contraction in the heart leading 
to an elevation of blood pressure.
146
 Administering noradrenaline to resveratrol-
nitroxide 12 fed DOCA-salt hypertensive rats lowered the contractile response below 
that of the UNX rats. However this is contrary to the previous observation in which 
the DOCA-salt hypertensive rats had a lower contractile response to noradrenaline 
than the UNX rats and treatment with resveratrol improved the contractile response 
(Figure 4.5A). Treatment of the thoracic aortic rings with sodium nitroprusside (a 
vasodilator drug used for induction of hypotension
147
 caused a reduced relaxant 
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response to the DOCA rats, whereas in the DOCA+NitroRes rats it failed to induce a 
reduction in relaxation. In fact it further reduced the relaxant response (see Figure 4.4 
(B)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 4:  Cumulative concentration-response curves for noradrenaline (A), 
Sodium nitroprusside (B) and acetylcholine (C) in the thoracic aortic rings from 
UNX, DOCA and NitroResveratrol treated rats. 
 
Treatment of the isolated thoracic aortic rings with acetylcholine (blood vessel 
relaxant) caused a reduction in relaxation response in the DOCA rats and it 
attenuated the reduced relaxation response in the DOCA rats treated with resveratrol-
nitroxide 12 (Figure 4.4 (C)). It has previously been reported that acetylcholine acts 
on resveratrol treated rats through its antioxidant ability by increasing the synthesis 
A B 
C 
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of nitric oxide which in turn causes expression of the protein sirtuin which possess 
histone deacetylase activity.
143
 Histone deacetylase is known to improve 
cardiovascular structure and function in DOCA-sat hypertensive rats possibly 
through inflammation suppression.
144
 Therefore acetylcholine might act on 
resveratrol-nitroxide 12 treated DOCA rats through the same mechanism.  
 
 
 
Figure 4. 5: Cumulative concentration-response curves for noradrenaline (A), 
Sodium nitroprusside (B) and acetylcholine (C) in the thoracic aortic rings from 
UNX, DOCA, UNX+ Resveratrol and DOCA+Resveratrol treated rats. 
 
The DOCA rats had a slight increase in weight of their left ventricle relative to the 
UNX rats. Treatment with resveratrol-nitroxide 12 failed to normalise this weight 
increase (Figure 4.6). This suggests that this compound (12) may not be able to 
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attenuate cardiac hypertrophy but like the previous observations further experiments 
are necessary to confirm this. 
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Figure 4. 6: Effects of resveratrol-nitroxide on UNX, DOCA and 
DOCA+NitroResveratrol rats. 
 
In conclusion, the resveratrol analogue 12 has demonstrated a promising effect on the 
hypertensive DOCA-salt rat model. This compound caused a reduction in the overall 
systolic blood pressure of the rat models by causing physiological changes in the 
body such as reduction in water intake and relaxant response of isolated thoracic 
aortic rings towards acetylcholine. It is also worth mentioning that compound 12, 
failed to improve contractile response and relaxant response of isolated thoracic 
aortic rings towards noradrenaline and sodium nitroprusside respectively. Currently 
additional experiments with a larger sample size of rats are underway to confirm 
these preliminary findings. 
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5.0. CONCLUSIONS AND FUTURE WORK 
 
A new facile method for direct aryl iodination of isoindoline and isoindoline 
nitroxide using periodic acid and potassium iodide in concentrated sulphuric acid has 
been devised. The reaction is complete in less than 3 hours and the work up is 
relatively simple. 
 
For aryl diiodination of the tetramethyl isoindoline and the tetramethyl isoindoline 
nitroxide, relatively pure crude compounds were obtained. Subsequent purification 
with silica column chromatography gave compound 21 in a 70% isolated yield and 
compound 22 in an 82% isolated yield. In the case of mono-iodination, modest yields 
of 39% for compound 17 and 48% for compound 18 were obtained. These seemingly 
low yields for mono-iodinations were due to the lack of deactivation of the 
isoindoline aromatic rings to further iodination after following mono-iodination. 
 
Diiodination of tetraethyl isoindoline was successfully carried out with pure di-iodo 
compound 27 obtained in a good yield of 80%. The tetraethyl isoindoline nitroxide 
29 was synthesised in a modest yield of 37%, diiodinated and monoiodinated 
tetraethyl isoindoline nitrones were also formed in 8% and 13% yields, respectively, 
with the latter being a mixture of regioisomers. Monoiodinated tetraethyl isoindoline 
was also synthesised however due to difficulties involved in its purification, it was 
directly oxidised with mCPBA into the tetraethyl isoindoline nitroxide 28 in a yield 
of 34% over the two steps.  
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Thus a range of monoiodinated and diiodinated isoindoline and isoindoline 
nitroxides have been prepared. These compounds can be used as coupling partners 
for making more complex isoindoline containing compounds for various applications 
such as profluorescent probes or antioxidants in biological systems. 
 
Nitroxide bearing analogues of resveratrol have been synthesised by using Heck 
coupling of 3,5-diacetoxy styrene 34 with 5-iodo-1,1,3,3-tetramethylisoindolin-2-
yloyl 18 or diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22 to generate the respective 
compounds 12 and 13. Starting material 34 was made employing the Wittig reaction 
from 3,5-dihydroxybenzylaldehyde followed by subseqnet acetylation. Attempts to 
improve the previously reported yield of 55-78%
93
 for compound 12 failed as the 
maximum obtained yield is 60%, nevertheless, this is within the reported yield range. 
In addition, since this new method used different starting materials than the one 
reported in literature, it provided an alternative route for making compound 12. The 
di-Heck product 13 was obtained in a poor yield of 1.6%, however, this could 
probably be improved with further optimization in the future.  
 
Administration of compound 12 to hypertensive DOCA-salt rat models caused a 
reduction in water consumption and normalisation of systolic blood pressure. 
Furthermore, DOCA-salt hypertensive rats administered compound 12 had improved 
response to acetylcholine induced thoracic aortic ring relaxation response compared 
to the untreated DOCA-salt rats. On other hand, the isolated thoracic aortic ring of 
DOCA-salt hypertensive rats treated with compound 12 failed to exhibit improved 
contractile and relaxant response after treatment with noradrenaline and sodium 
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nitroprusside, respectively. This compound also did not significantly improve the 
food intake of the hypertensive DOCA-salt rats nor did it alleviate the ventricular 
hypertrophy observed in the DOCA rats. It must be pointed out that the experiments 
were done on small sample sizes, this is apparent on the graphs. 
 
As has been pointed out before, the next challenge in this project is to test the 
reproducibility of the biological effects of compound 12 discussed previously on a 
larger DOCA-salt hypertensive rat population size. This is currently being carried out 
within Lindsay Brown’s group at USQ. After optimisation of the yield of compound 
13, it will be subjected to similar biological studies to test its effect on the 
hypertensive DOCA-salt rat models. Resveratrol, the parent compound upon which 
the structure of the above two compounds is based, will also be included in this 
round of testing for direct comparison of the results. Separate samples of a nitroxide 
and resveratrol will also be administered simultaneously. As mentioned earlier in 
chapter 1, both resveratrol and nitroxide have shown potential for treatment of cancer 
and neurodegenerative diseases (e.g. Alzheimer’s disease and Parkinson’s disease). 
Thus there are also future plans to extend the study of the biological effects of 
compounds 12 and 13 towards cancer and neurodegenerative disease models. 
As an extension of this project, analogues of resveratrol bearing tetraethyl nitroxides 
25 will also be prepared. The reduction of compound 25 into the nitrone compound 
55 (evolving ethylene) in the reaction vessel seems to present an interesting problem 
for  in vivo or in vitro studies as the bioavailability of the nitroxide (25) will be 
reduced. However, it has been reported in literature that the tetraethyl nitroxide is 
known to be less susceptible to bioreduction than the tetramethyl nitroxide, in fact it 
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displays a half life of up to 200 hours compared to 25 hours for the methyl nitroxide 
at room temperature in human blood
148
. It will therefore be interesting to investigate 
the biological effect of introducing the tetraethyl nitroxide into the structure of 
resveratrol 1 to make the analogues 40 and 41 shown below.  
 
Other resveratrol analogues that could be prepared using tetramethyl and tetraethyl 
based nitroxides are shown below. 
40 
41 
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6.0. EXPERIMENTAL 
 
6.1 General Methods  
 
All synthetic work carried out at the Queensland University of Technology and 
biological experiments were performed in Prof. Lindsay Browns’s group at the 
University of Southern Queensland (Toowoomba). 
All starting materials and reagents were purchased from Sigma Aldrich. All reactions 
were monitored by Merck Silica Gel 60 F254 TLC and visualized with UV light. 
Silica gel column chromatography was performed using silica gel 60 Å (230 - 400 
mesh).  
Anhydrous toluene and diethyl ether were stored over sodium wires to get rid of 
moisture. Anhydrous THF was obtained by distilling over sodium/benzophenone 
under argon gas immediately prior use. 
1
H NMR spectra were run at 400 MHz and 
13
C NMR spectra at 100 MHz on Avance 
400 Bruker. Chemical shifts ( ) for 
1
H and 
13
C NMR spectra run in CDCl3 are 
reported in ppm relative to the solvent residual peak: proton (  = 7.26 ppm) and 
carbon ( = 77.2 ppm). Multiplicity is indicated as follows: s (singlet); d (doublet); t 
(triplet); m (multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet); 
br s (broad singlet). Coupling constants are reported in Hertz (Hz). Mass spectra 
were recorded using electrospray and electron impact (where specified) as the 
ionization technique in positive ion mode. All MS analysis samples were prepared as 
solutions in methanol.  
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Infrared spectra were recorded as neat samples using a Nicolet 870 Nexus Fourier 
Transform infrared spectrometer equipped with a DTGS TEC detector and an 
Attenuated Total Reflectance (ATR) accessory (Nicolet Instrument Corp., Madison, 
WI) using a Smart Endurance single reflection ATR accessory equipped with a 
composite diamond IRE with a 0.75 mm
2
 sampling surface and a ZnSe focussing 
element. An Optical Path Difference (OPD) velocity of 0.6329 cm s
-1 
and a gain of 8 
were used. Spectra were collected in the spectral range 4000-525 cm
-1
 with a 
minimum of 16 scans, and 4 cm
-1
 resolution.  
 
Analytical HPLC was performed on a Hewlett Packard 1100 series HPLC, using an 
Agilent prep-C18 scalar column (10 μm, 4.6 × 150 mm) at a flow rate of 1 mL/min.  
 
Melting points were measured on a Gallenkamp Variable Temperature Apparatus by 
the capillary method and are uncorrected. 
 
 
6.2. Synthesis of 3,5-dihydroxy styrene (33). 
 
OHHO
33
Hb
Ha
H
1
2
3
4
5
6
7
8
 
A suspension of sodium hydride (dry powder, 198 mg, 8.24 mmol) in anhydrous 
DMSO (3 mL) was heated at 70 
o
C under an atmosphere of argon for 1 hour. The 
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cream coloured solution was then cooled in ice bath and methyltriphenylphophonium 
bromide (2.94 g, 8.24 mmol) in anhydrous DMSO (7 mL) was added. The resulting 
reaction mixture was stirred for 15 minutes on ice. A solution of 
dihydroxybenzaldehyde (285 mg, 2.06 mmol) in anhydrous DMSO (2 mL) was 
added to the yellow reaction mixture and stirring was continued for 2 hours. After 
this time, the reaction (now green) was quenched by the addition of a mixture of 
ice/diethyl ether (~ 30 mL), acidified with 5 M aqueous HCl and extracted with 
diethyl ether (3 × 100 mL). The combined organic layers were washed with brine (2 
× 30 mL). The combined organic layers were dried with sodium sulphate and the 
solvent was removed under reduced pressure to give crude product 33 (1.2 g) as a 
colourless oil. Purification by silica gel column chromatography in DCM/diethyl 
ether (1/3) yielded 33 as a sticky white solid (0.255 g, 91%); 
1
H NMR (400 MHz, 
DMSO): δ 9.21 (s, 2H, 2 × OH), 6.53 (dd, J = 11.2, 17.2 Hz, 1H, 2-H), 6.30 (s, 2H, 
4-H and 8-H), 6.14 (s, 1H, 6-H), 5.62 (d, J = 17.6, Hz, 1H, 1a-Htrans), 5.15 (d, J = 
11.2, Hz, 1H, 1b-Hcis): MS (EI) m/z 136 (M
+ 
100]. The obtained 
1
H NMR data was 
consistent with that previously reported in the literature.
138
  
 
6.3. Synthesis of 3,5-diacetoxy styrene (34). 
 
 
Pyridine (0.38 mL, 4.37 mmol, 2.5 eqv.) and DMAP (2.2 mg, 0.018 mmol, 9.7 × 10
-3 
eqv.) were added to a solution of dihydroxystyrene 33 (255 mg, 1.87 mmol) in 
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anhydrous DCM (4 mL) at 0 
o
C under an atmosphere of argon. Acetic anhydride 
(0.44 mL, 4.68 mmol, 2.5 eqv.) was added and the resulting mixture was stirred 
under argon overnight at room temperature. The reaction mixture was concentrated 
at reduced pressure and the resultant product was purified by silica column 
chromatography (DCM/CHCl3 1:1) to give 34 as a colourless oil (334 mg, 81%); 
1
H 
NMR (400 MHz, CDCl3): δ 7.04 (d, J=11.0 Hz, 2H, 4-H and 8-H), 6.84 (s, 1H, 6-H), 
6.67 (dd, J = 10.8 Hz, 17.6 Hz, 1H, 2-H), 5.76 (d, J = 17.2, Hz, 1H, 1a-Htrans), 5.34 
(d, J = 10.8, Hz, 1H, 1b-Hcis), 2.31 (s, 6H, 2 × CH3). The obtained 
1
H NMR data was 
consistent with that previously reported in the literature.
138
  
 
6.4. Synthesis of N-benzylphthalimide (14). 
 
N
O
O
14
1
23
3a
4
5
6
7
7a
1'
2' 3'
4'
5 '6'
7'
 
Phthalic anhydride (10 g, 67.5 mmol), benzylamine (11.12 mL, 101.84 mmol, 1.52 
eqv.) and glacial acetic acid (47 mL) were reflux for 1 hour. While still hot the 
reaction mixture was poured onto ice/water (150 mL). The precipitated product was 
collected by filtration and recrystallised from ethanol to give 14 as white needle like 
crystals (15.04 g, 94%): M.p. 115-117°C, (lit.
113
 113-115 °C);
 1
H NMR (400 MHz, 
CDCl3): δ 7.87 (dd, 2H, J =3 .2 Hz and 5.4 Hz, 5-H and 6-H), 7.73 (dd, 2H, J = 3.2 
Hz and 5.6 Hz, 4-H and 7-H), 7.46 (d, 2H, J =7 .2 Hz , 3-H
’
 and 7-H
’
), 7.32 (m, 3H, 
4-H
’
, 5-H
’
 and 6-H
’
), 4.87 (s, 2H, CH2); HRMS: calculated for C15H12NO2 [MH
+
] 
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238.0790; found 238.0791 These data agree with those previously reported by Hsieh 
et al.
113
 
 
6.5. Synthesis of 2-benzyl-1,1,3,3-tetramethylisoindoline (15). 
 
 
To a pre-dried 3000 mL round bottom flask fitted with a thermometer, dropping 
funnel and dean stark connected to a condenser was added a few crystals of iodine 
and activated (80 
o
C 24 hrs) magnesium turnings (120 g, 4.94 mol 11.7 eqv).The 
system was heated with heat gun while connected under high vacuum until the iodine 
crystals had sublimed. The system was placed under an atmosphere of argon and 
allowed to cool. Anhydrous diethyl ether (1500 mL) was introduced and 
iodomethane (155 mL, 2.48 mol, 5.9 eqv.) was added dropwise to this with constant 
gentle stirring (over a period of 2.5hrs). The grey coloured solution was then 
concentrated by heating until the interior temperature reached 80 
o
C. Upon cooling 
the reaction mixture to 64 
o
C, a solution of N-benzylpthalimide (100 g, 0.42 mol) in 
anhydrous toluene (1000 mL) was added at such a rate as to maintain a constant 
temperature. Following this addition, diethyl ether was further removed by 
distillation until a temperature of 110 
o
C was reached. The reaction mixture was then 
heated at 110 
o
C for 3 hrs. The mixture was concentrated by increasing the 
temperature to 120 
o
C and then allowed to cool. Once cooled, hexane (1500 mL) was 
added and the mixture was filtered through celite. The now purple filtrate was 
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bubbled with air overnight to dryness and passed through a short column of basic 
alumina using hexane. Concentration of the hexane layers gave a white solid which 
was recrystallised from methanol to give 15  as colorless crystals (25 g, 23%): M.p. 
62-64 
o
C,(lit.
114
63 - 64 °C). 
1
H NMR (400 MHz, CDCl3): δ 7.49 (d, J = 7.2Hz, 2H, 
3-H
’ 
and 7-H’), 7.23 – 7.33 (m, 5Harom), 7.15 (dd, J =3.2, 5.2 Hz, 2Harom), 4.01 (s, 
2H, CH2), 1.32 (s, 12H, 4 × CH3); MS [C19H24N] ([M+H]
+
): calc. 266.1903; found 
266.1896. These data agree with those previously reported by Griffiths et.al.
114
 
NB: Exposure of the Grignard residue to atmosphere must be avoided lest 
spontaneous combustion of excess activated magnesium and Grignard reagent. 
Unwanted residue must be quenched with propanol. 
 
6.5. Synthesis of 5-bromo-1,1,3,3-tetramethylisoindoline (16). 
 
 
2-Benzyl-1,1,3,3-tetramethylisoindoline 15 (2.0 g, 7.56 mmol) in anhydrous DCM 
(10 mL) was cooled to 0 
o
C under an atmosphere of argon. Bromine (0.85 mL, 16.63 
mmol, 2.2 eqv.) in DCM (16 mL) was added slowly (making sure temperature stayed 
at 0 
o
C). Anhydrous AlCl3 (3.52 g, 26.46 mmol, 3.5 eqv.) was then added and the 
reaction was allowed to stir at 0 
o
C for 1 hour. The yellow mixture was then poured 
into ice (approximately 50mL), stirred for 15 minutes and basified with aqueous 
NaOH (10 M) to pH 14. The resulting solution was extracted with DCM (3 × 100 
mL) and the combined organic layers washed with brine (60 mL). The solvent was 
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removed at reduced pressure to give a golden yellow oil. This product was taken up 
in methanol (20 mL) and NaHCO3 (100 mg) added. To this was added hydrogen 
peroxide (30%) until no further effervescence could be detected. Sulphuric acid (2 
M, ~ 40 mL) was added carefully and the mixture was washed with DCM (2 × 50 
mL). The organic phases were further extracted with sulphuric acid (2 M, 2 × 50 mL) 
and the combined acidic layers washed with DCM (50 mL). The acidic layers were 
then cooled on ice, basified with 10 M NaOH and extracted with DCM (3 × 70 mL). 
The combined organic phases were washed with brine (2 × 50 mL), dried over 
sodium sulphate and concentrated at reduced pressure to give 16 as a golden yellow 
product which slowly crystallised into a low melting white solid, (1.42 g, 74%); M.p. 
57-59 
o
C (lit
117
 58- 60 
o
C); 
1
H NMR (400 MHz, CDCl3): δ 7.38 (dd, 1H, J = 2.0 and 
8.0 Hz, 6-H), 7.26 (d, 1H, J 2.0 Hz, 4-H), 7.00 (d, 1H, J 8.0 Hz, 7-H), 1.66 (br, 1H, 
NH), 1.46 (s, 6H, CH3), 1.45 (s, 6H, CH3). These data agree with those previously 
reported by Bottle et.al.
117
  
 
6.7. Synthesis of 5-iodo-1,1,3,3-tetramethylisoindoline (17). 
 
 
5-Bromo-1,1,3,3-tetramethylisoindoline 16 (500 mg, 1.98 mmol) in anhydrous THF 
(6 mL) was cooled to -78 
o
C in a dry ice/acetone bath under an atmosphere of argon. 
Dropwise addition of n-butyllithium (1.6 M in hexane, 3.34 mL, 5.35 mmol, 2.7 
equivalents) was carried out whilst maintaining the temperature at -78 
o
C. The 
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resulting solution was stirred for a further 15 minutes at -78 
o
C. Iodine (750 mg, 5.93 
mmol, 3 equivalents) in anhydrous THF (10 mL) was added gradually and the 
reaction mixture was allowed to warm up to room temperature. The mixture was then 
poured onto ice/water (100 mL), basified with NaOH (5 M) and extracted with DCM 
(3 × 100 mL). The combined organic layers were washed with water and dried over 
sodium sulphate and the solvent was removed at reduced pressure. The resulting 
residue was dissolved in methanol (20 mL) and NaHCO3 (60 mg) was added. To this 
solution was added hydrogen peroxide (30%, 15 mL) dropwise. After the activity 
subsided, H2SO4 ( 2 M, 60 mL) was added. The solution was washed with DCM (3 × 
100 mL) and the combined organic phases back extracted with  H2SO4 (2 M, 3 × 100 
mL). Then the combine acidic aqueous phase was basified with NaOH (10 M) and 
extracted with DCM (3 × 200 mL), then the organic layers were washed with water 
(200 mL) and dried over sodium sulphate. The solvent was removed at reduced 
pressure to obtain 17 as a low melting white solid (442 mg, 74%); 
1
H NMR (400 Hz, 
CDCl3): δ 7.58 (dd, 1H, J = 1.6 and 8.0 Hz, 6-H), 7.46 (d, 1H, J = 1.2 Hz, 4-H), 6.90 
(d, 1H, J = 8.0 Hz, 7-H), 1.61 (s, br, NH), 1.45 (s, 12H, CH3). HRMS [C12H16IN]
+ 
([M+H]
+
): calc. 302.0327, found 302.033. These data agree with those previously 
reported by Bottle et.al.
76 
 
 
6.8. Synthesis of 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl (18). 
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A solution of 5-iodo-1,1,3,3-tetramethylisoindoline 17 (846 mg, 2.75 mmol) in DCM 
(35 mL) was cooled to 0
o
C. mCPBA (77%, 143 mg, 6.33 mmol, 2.30 eqv.) was 
added and the mixture was stirred for 20 minutes at 0
o
C and then allowed to warm up 
to room temperature overnight. Water (20 mL) was added and the mixture was 
extracted with DCM (3 × 100 mL). The combined organic phases were washed with 
NaOH (2M, 3 × 50 mL) and brine (100 mL) and dried over sodium sulphate. The 
solvent was removed at reduced pressure to give crude 18 as a yellow solid (0.873 
mg). Recrystallisation from ethanol produced 18 as a yellow solid (719 mg, 84%); 
M.p. 133-135 
o
C (lit. 132-135 
o
C).
76
 HRMS [C12H15INO]
+
 [M
+
]: calc. 316.0198, 
found 316.0204. These data agree with those previously reported by Bottle et. al.
76
 
 
6.9. Synthesis of (E)-5-(2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)vinyl)-1,3-phenylene diacetate (35). 
 
3,5-Dihydroxystyrene 34 (230 mg, 1.04 mmol, 1.3 eqv.), 5-iodo-1,1,3,3-
tetramethylisoindolin-2-yloyl 17 (254 mg, 0.80 mmol), palladium acetate (8.20 mg, 
0.037 mmol, 0.05 eqv.), PPh3 (19.1 mg, 0.073 mmol, 0.1 eqv.) and anhydrous 
potassium carbonate (192 mg, 1.39 mmol, 1.9 eqv.) were added to a schlenk tube 
under argon gas with anhydrous DMF (7 mL). The reaction mixture was then 
degassed (5 × freeze pump thaw cycles), charged with argon, sealed and stirred for 
46 hours at 120 
o
C. Water (40 mL) was then added to the resulting dark-brown 
mixture and the solution was extracted with diethyl ether (3 × 150 mL). The 
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combined organic layers were washed with brine (2 × 50 mL) and dried with sodium 
sulphate. The solvent was removed at reduced pressure to give crude 35 as a dark 
brown oily solid which was purified with silica gel chromatography employing 
DCM/diethyl ether (9/1) to obtain 35 as a white fluffy solid (294 mg). M.p. 74-77 
o
C; 
HRMS [C24H26NO5] [M]
+
: calc. 408.1811, found 408.1821; Elemental analysis: 
calcd (%) for C24H26NO5: C 70.57, H 6.42, N 3.64; found C 70.10, H 6.49, N 3.64. 
 
6.10. Synthesis of (E)-5-(2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)vinyl)-1,3-phenylene diol (12). 
 
 
A solution of (E)-5-(2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)vinyl)-1,3-
phenylene diacetate 35 (146 mg, 0.358 mmol) and potassium carbonate (148 mg, 
1.07 mmol) was stirred in a mixture of THF (5 mL), MeOH (7 mL) and H2O (7 mL) 
at room temperature overnight. The reaction mixture was concentrated and then 
acidified with aqueous HCl (2 M). The aqueous solution was extracted with diethyl 
ether (3 × 150 mL) and the combined organic layers were washed with brine and 
dried over sodium sulphate. The solvent was evaporated to give a dark brown residue 
(146 mg) which was purified by silica gel column chromatography (DCM/diethyl 
ether, 9:1) to give 12 as a cream coloured solid (95 mg, 82%); M.p. 213-214 
o
C, 
HRMS [C20H22NO3] [M
+
]: calc. 324.1600, found 324.1604. Elemental analysis: 
calcd (%) for C20H22NO3: C 74.05, H 6.84, N 4.32; found C 73.525, H 6.76, N 4.18. 
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The sample was ≥ 98% pure as indicated by analytical HPLC (70% MeOH, 30% 
H2O). 
 
6.11. Synthesis of (E)-5,6-(2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)vinyl)-di-(1,3-phenylene diol) (13). 
 
The same procedures used to make compounds 35 and 12 were used to make 
compound 13. This involved heating a mixture containing 3,5-dihydroxystyrene 34 
(142 mg, 2.4 eqv., 0.65 mmol), 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22 
(118 mg, 1eqv., 0.27 mmol), Pd(OAc)2 (6.10 mg, 0.10 equivalents, 0.30 mmol), 
triphenylphosphine (13.8 mg, 0.2 eqv., 0.05 mmol) and potassium carbonate (141.5 
mg, 3.8 eqv., 1.02 mmol) in anhydrous DMF (3.5 mL) at 120 
o
C for 24 hours (TLC 
indicated disappearance of 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloyl 22).  The 
work up was carried out by adding water (20 mL) to the dark brown mixture which 
was then extracted with diethyl ether (3 x 100 mL). The combined organic layers was 
then washed with brine (2 x 75 mL), dried over sodium sulphate and solvent 
removed at reduced pressure to obtain 73.1 mg of the crude compound. The crude 
compound crude compound was then separated with silica gel chromatography (50% 
ethyl acetate in hexane) to give three separate fractions. The fraction were identified 
with ESI HRMS to be (1) monoacetylated derivative [C30H30NO6] [M+2H]
+
: 
calc.=502.2073 m/z found 502.2235 m/z (2) diacetylated derivative [C32H32NO7] 
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[M+2H]
+
: calc.=544.2179 m/z found 544.2343 m/z  (3) triacetylated derivative 
[C34H34NO8] [M+2H]
+
: calc.=586.2284 m/z found 586.2450 m/z. the fraction were 
then combined and treated with 2M NaOH solution (5 mL) and left to stir overnight. 
The resulting solution was acidified with 2 M HCl and extracted with diethyl ether (3 
× 30 mL). Purification using silica gel column chromatography (eluent 70% ethyl 
acetate in hexane) gave the desired compound 13 (7.2 mg, 1.6%). MS [C28H28NO5 ] 
[M
+
]: calc. 458.1962 m/z found 458.1967 m/z. Analytical HPLC (eluent 70% 
methanol in water) showed 94% purity (figure A.11 in the appendix). 
 
6.12. Synthesis of 1,1,3,3-tetramethylisoindoline (19). 
 
 
2-Benzyl-1,1,3,3-tetramethylisoindoline 15 (1.5 g, 5.4 mmol) in glacial acetic acid 
(40 mL) in the presence of 10% Pd/C (140 mg) catalyst was placed under an 
atmosphere of hydrogen gas in a Parr hydrogenator for 4 hours at 60 Psi. The 
reaction mixture was filtered and the filtrate concentrated and basified with 10 M 
NaOH. The basified mixture was extracted with ethyl acetate (4 × 100 mL) to give 
19 as a colourless oil (851 mg, 90%): M.p. 37-39 
o
C (lit.
114
 36-38 
o
C); 
1
H
 
NMR 
(400MHz, CDCl3): δ 7.26 (dd, 2H, J 3.2 and 5.6 Hz, 5-H and 6-H), 7.15 (dd, 2H, J 
3.2 and 5.6 Hz, 4-H and 7-H), 1.78 (br, 1H, NH), 1.48 (s, 12H, CH3). The product 
was sufficiently pure to be used in the next step without further purification. 
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GENERAL EXPERIMENTAL PROCEDURE FOR DIRECT 
ARYL IODINATION 
6.13. A representative procedure for the synthesis of compound (21): 
Potassium iodide (121 mg, 0.73 mmol) was added portionwise to a solution of 
periodic acid (56 mg, 0.24 mmol) in sulphuric acid (98% conc., 10 mL) at 0 
o
C. The 
resulting dark-brown solution was stirred for 15 min. and 1,1,3,3-
tetramethylisoindoline 19 (61 mg, 0.348 mmol) was added. The reaction was allowed 
to stir for 3 hrs at the end of which time the reaction mixture was poured onto ice and 
basified with NaOH (10 M) solution to pH 14. The aqueous solution was then 
extracted with dichloromethane (3 × 100 mL) and the combined organic layers 
washed with saturated sodium thiosulphate solution (2 × 100 mL) and brine (1 × 100 
mL). The organic phases were then dried with sodium sulphate and the solvent 
removed to give crude 21 (139 mg). The residue was purified by silica gel column 
chromatography (DCM/diethyl ether = 6/4) to afford compound 21 as a white 
powder. 
5, 6-diiodo-1, 1, 3, 3-tetramethylisoindoline (21). 
 
Yield 70% (103.8 mg); M.p. 122 -124 
o
C; 
 1
H NMR (400 MHz, CDCl3): δ 7.64 (s, 
2H), 1.60 (s, 1H), 1.44 (s, 12H); 
13
C NMR (CDCl3): δ 151.39, 132.66 , 105.63 , 
62.41 , 31.61 ; MS [C12H16I2N]
+
 ([M + H]
+
): calc. 427.9294, found:427.9400. 
Elemental analysis: calcd. (%) for C12H16I2N: C 33.75, H 3.54, N 3.28: found C 
33.54, H 3.46, N 3.18. 
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6.14. Synthesis of 5-iodo-1, 1, 3, 3-tetramethylisoindoline (17).  
 
 
This compound was synthesised using the general experimental procedure described 
above employing 0.11 mmol of periodic acid, 0.34 mmol of potassium iodide, 0.41 
mmol of 1,1,3,3-tetramethylisoindoline 19 and sulphuric acid (98% conc., 6 mL) 
were used. Analysis of the crude product by 
1
H NMR indicated a mixture containing 
31% compound 21 and 69% compound 17. Silica column chromatography in a 
gradient from DCM to diethyl ether yielded desired compound 17 as a low melting 
cream solid (48 mg, 39%).  
1
H NMR (400Hz, CDCl3): δ 7.58 (dd, 1H, J = 1.6 and 8.0 
Hz, 6-H), 7.46 (d, 1H, J = 1.2 Hz, 4-H), 6.90 (d, 1H, J = 8 Hz, 7-H), 1.61 (s, br, NH), 
1.45 (s, 12H, CH3); HRMS [C12H16IN]
+ 
([M+H]
+
): calc. 302.0327, found 302.033. 
6.15. Synthesis of 1,1,3,3-tetramethylisoindolin-2-ylxoyl  (20). 
 
 
A solution of 1,1,3,3-tetramethylisoindoline 19 (11.4 mmol)  in DCM (50 mL) was 
cooled to 0 
o
C, then mCPBA (2 eqv, 22.8 mmol) was added and resulting solultion 
was stirred at 0 
o
C for further 20 minutes. The reaction mixture was then allowed to 
come to room temperature over a period of 2 hours, then water (30 mL) was added 
and the mixture was extracted with DCM (3 × 100 mL). The organic layer was 
washed with 2 M sodium hydroxide (2 × 50 mL) and with brine (1 × 70 mL), then 
dried with sodium sulphate and the solvent removed at reduced pressure to give the 
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crude compound as yellow solid. Silica column chromatography using DCM/diethyl 
ether (9/1) gave compound 20 as yellow powdery solid (1.74 g, 80%). M.P. 129 – 
131 
o
C (Lit.
114
 128 – 131 oC), HRMS (EI) [C12H16NO] [M
+
] calc. 190.1232, found 
190.1202. Analytical HPLC in methanol/water (8/2) showed a single peak at 2.89 
minutes. 
 
6.16.  Synthesis of 5,6-diiodo-1,1,3,3-tetramethylisoindolin-2-yloxyl  (22). 
 
 
Compound 22 was prepared according to the general procedure above using 0.24 
mmol of periodic acid, 0.72 mmol of potassium iodide, 0.267 mmol of 1,1,3,3-
tetramethylisoindolin-2-yloyl 20 and sulphuric acid (98% conc., 7 mL). The 
disappearance of the starting material and appearance of the product was monitored 
using analytical HPLC, after 2.5 hrs all the starting material has disappeared and 
95% of the reaction mixture contained product 2. The crude residue (113 mg) was 
purified using silica chromatography (DCM) to yield the desired compound 22 as a 
yellow solid (97 mg, 82%).M.P. = 262 – 264 oC; HRMS (EI) [C12H14I2NO] [M
+
] 
calc. 441.9165, found 441.9159. Elemental analysis: calcd (%) for C12H14I2NO: C 
32.60, H 3.19, N 3.17: found C 32.57, H 3.09, N 3.12. 
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6.17. Synthesis of 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl (18).   
 
 
This reaction was carried out as outlined in the general procedure above using 0.277 
mmol of periodic acid, 0.83 mmol of potassium iodide, 1.58 mmol 1,1,3,3-
tetramethylisoindolin-2-yloyl 20 and DCM (8 mL). The reaction was followed by 
analytical HPLC for 2.5 hrs after which time 70% of 18, 18% of starting material 
(TMIO) and 3% compound 22 were observed in the crude product (393 mg). Silica 
gel chromatography in DCM yielded the desired product 18 as a yellow solid (240.3 
mg, 48%). The starting material 20 was also recovered (107 mg, 37%). M.P. 132 – 
134 
o
C (lit.
76
 132 – 135 oC); HRMS (EI) [C12H15INO] ([M]): calc. 316.0198, found 
316.0204. 
 
6.18.  Synthesis of 1,1,3,3-tetraethylisoindoline (24). 
 
 
Compound 24 was prepared using the procedure described for compound 19 with 2-
benzyl-1,1,3,3-tetraethylisoindoline (2.5g, 7.78 mmol) in glacial acetic acid (30 mL) 
with 10% Pd/C catalyst (250 mg, 0.23mmol). The target compound was obtained as 
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a colourless oil (1.67 g, 93%). 
1
H NMR (400 MHz, CDCl3): δ 7.26 (m, 2H, H-5 and 
H-6), 7.09 (m, 2H, H- 4 and H-5), 1.70 (m, 8H, CH2), 1.28 (s, br, NH), 0.90 (m, 12H, 
4 × CH3).   
 
6.19.  Synthesis of 1,1,3,3-tetraethylisoindolin-2-yloxyl (25). 
 
 
1,1,3,3-Tetraethylisoindoline 24 (1.05 mmol) was dissolved in DCM (8 mL) then 
cooled to 0
o
C and mCPBA (77%, 2.3 equivalents, 2.42 mmol) was added. The 
procedure used to prepare compound 20 was then followed. After silica column 
chromatography in DCM compound 25 was obtained as yellow solid (194 mg, 
75%).HRMS (EI) [C16H24NO]
+
 [M]
+
: calc. 246.1858, found 246.1858. Analytical 
HPLC (95% methanol in water) showed the compound to be 96% pure, see appendix 
for chromatogram. 
6.20.  Synthesis of 5,6-diiodo-1,1,3,3-tetraethylisoindoline (27). 
 
 
The synthesis of compound 27 was undertaken using the experimental procedure 
outlined above for direct iodination. In this case, 0.506 mmol of periodic acid, 1.517 
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mmol of potassium iodide, 0.562 mmol of 1,1,3,3-tetraethylisoindoline 24 and 
sulphuric acid (98% conc., 6 mL)were used. Compound 27 was obtained as a white 
coloured solid (216 mg, 80%). 
1
H NMR (400MHz, CDCl3): δ 7.58 (s, 2H), 1.73 – 
1.55 (m, 9H), 0.88 (t, J = 7.2 Hz, 12H); 
13
C NMR (400MHz, CDCl3): δ 150.2, 133.4, 
105.2, 68.2, 33.5, 8.1; HRMS (EI) [C16H24I2N]
+
 ([M+H]
+
): calc. 483.9920, found 
484.0022; Elemental analysis: calcd (%) for C12H16I2N: C 33.75, H 3.54, N 3.28: 
found C 33.54, H 3.46, N 3.18. 
 
6.21. Synthesis of 5-iodo-1,1,3,3-tetraethylisoindoline (26) and 5-iodo-
1,1,3,3-tetraethylisoindolin-2-yloxyl (28). 
 
 
Following the general experimental procedure, compound 26 was synthesised from 
0.73 equivalents of I
+
 using 0.315 mmol of periodic acid, 0.945 mmol of potassium 
iodide, sulphuric acid (98% conc., 10 mL) and 1.730 mmol of 1,1,3,3-
tetraethylisoindoline 24. After work up, a pale yellow oily crude product (460 mg) 
was obtained which was shown by analytical HPLC and 
1
H
 
NMR spectroscopy to 
contain the starting material 1,1,3,3-tetraethylisoindoline 24, compound 26 and 
compound 27 in a ratio of 1:6:1. These three components could not be resolved on 
TLC and therefore were not separated using silica gel chromatography. The crude 
product was then oxidised into a mixture of nitroxides by treating with mCPBA (0.68 
g, 77%, 3.03 mmol) in DCM (20 mL) at 0 
o
C for 20 minutes. The reaction mixture 
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was then allowed to come to room temperature over a 2 hr period. The reaction was 
quenched with water (20 mL) and the organic phase washed with NaOH (2 M, 3 × 
50mL), brine (100 mL), dried over sodium sulphate and the solvent removed at 
reduced pressure to give an oily yellow crude product. Purification using silica gel 
chromatography gave 216 mg (48% based on 0.7 I
+
) of 28 as a yellow viscous liquid, 
118 mg (28% based on number of moles of TEI 24) of 25 as a yellow powdery solid: 
only traces of 29 were detected. Data for compound 28: HRMS (EI) ([C16H23INO]
+
) 
(M
+
): calc. 372.0824, found 372.0827; Data for compound 25: EI HRMS 
[C16H24NO]
+
 [M]
+
: calc. 246.1858, found 246.1858. 
 
6.22.  Synthesis of 5,6-diido-1,1,3,3-tetraethylisoindolin-2-yloxyl (29). 
                                   
 
The reaction used to synthesise compound 29 was carried out as per the general 
procedure with 0.325 mmol of periodic acid, 0.975 mmol of potassium iodide, 0.325 
mmol of 1,1,3,3-tetraethylisoindolin-2-yloyl 25 and 6 mL of sulphuric acid (98% 
conc., 6 mL). A crude sample was obtained 143 mg, purification by silica gel 
chromatography (chloroform) gave compound 29 as a yellow powder (59 mg, 37%), 
along with compound 30 as a white powder (14 mg, 8.4%) and compound 31 (20.6 
mg,12.7%) as a yellow oil.  Data for 29: M.p. 79-81
o
C; MS (EI) m/z 498 (M
+
, 70). 
The sample was ≥ 98% pure according to analysis by analytical HPLC (95% MeOH, 
5% H2O). 
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Data for 30: M.p. 98-100 
o
C. 1H NMR (400 MHz, CDCl3): δ 7.85 ( s, 1H, Ar-H), 7.70 
(s, 1H, Ar-H), 2.81 (q, J = 7.5 Hz, 2H, 1 x CH2), 2.11-2.21 (m, 2H, 1 x CH2), 1.81-
1.92 (m, 2H, 1 x CH2), 1.26 (t, J =7.4 Hz, 3H, 1 x CH3), 0.44 (t, J = 7.4 Hz, 6H, 2 × 
CH3)  
13
C NMR (400MHz, CDCl3): δ 145.6, 141.8, 137.4, 131.2, 128.7, 107.2, 106.0, 
83.8, 29.8, 16.8, 9.9, 7.3; HRMS (EI) [C14H17I2NO]
+
: calc. 469.9400, found 
498.9487. The sample was ≥ 98% pure following analysis by analytical HPLC (95% 
MeOH, 5% H2O).  
 
Data for 31: Inseparable mixture. Products formed in a 3:2 ratio by 
1
H NMR 
analysis; major isomer: 1H NMR (400MHz, CDCl3): δ 7.67-7.71 (m, 2H, Ar-H), 6.96 
(d, J = 8.3 Hz, 1H, Ar-H), 2.80-2.90 (m, 2H, CH2), 2.11-2.24 (m, 2H, CH2), 1.83-
1.95 (m, 2H, CH2), 1.23-1.32 (m, 3H, CH3), 0.38-0.48 (m, 6H, 2 × CH3) minor 
isomer: 1H NMR (400MHz, CDCl3): δ 7.73 (dd, J1,2 = 8.1 Hz, J1,3 = 1.3 Hz, 1H, Ar-H), 
7.54 (d, J1,2 = 1.4 Hz, 1H, Ar-H), 7.12 (d, J1,2 = 8.1 Hz, 1H, Ar-H), 2.80-2.90 (m, 2H, 
CH2), 2.11-2.24 (m, 2H, CH2), 1.83-1.95 (m, 2H, CH2), 1.23-1.32 (m, 3H,  CH3), 
0.38-0.48 (m, 6H, 2 × CH3); 
13
C NMR (100MHz, CDCl3): δ 146.9, 146.1, 142.7, 140.0, 
137.9, 135.9, 135.2, 129.7, 127.5, 122.5, 120.0, 93.2, 92.8, 83.9, 83.6, 30.0, 29.9, 
16.9, 9.9, 7.2; HRMS (EI) [C14H18INO]
+
: calc. 344.0433, found 344.0525. The 
sample was ≥ 98% pure according to analysis by analytical HPLC (95% MeOH, 5% 
H2O). 
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APPENDIX 
 
Figure A. 1:
 1
H NMR spectrum (400 MHz, CDCl3) for compound 21. 
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Figure A. 2:  13NMR spectrum (400 MHz, CDCl3) for compound 21. 
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Figure A. 3: 
1
HNMR spectrum (400 MHz, CDCl3) for compound 27. 
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Figure A. 4:  
13
CNMR spectrum (400 MHz, CDCl3) for compound 27. 
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Figure A. 5: 
1
HNMR spectrum (400MHz, CDCl3) for compound 30. 
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Figure A. 6: 
13
CNMR spectrum (400MHz, CDCL3) for compound 30. 
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Figure A. 7: 
1
HNMR spectrum (400MHz, CDCl3) for compounds 31. 
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Figure A. 8: 
13
CNMR spectrum (400MHz, CDCl3) for compounds 31. 
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Figure A. 9: Compound 25, HPLC chromatogram (eluent 95% methanol in water). 
 
 
 
Figure A. 10: Compound 28, HPLC chromatogram (eluent 95% methanol in water). 
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Figure A. 11: Compound 12, HPLC chromatogram (eluent 70% methanol in water). 
 
 
 
Figure A. 12: Compound 13, HPLC chromatogram (eluent 70% methanol in water).
  
 
 
 
References 
130 
 
REFERENCES 
 
 (1) Halliwell, B. Free Rad. Res. Comms 1990, 9, 1.  
 (2) Bayir, H. Crit. Care Med. 2005, 33, S498.  
 (3) Dhalla, N. S.; Temsah, R. M.; Netticadan, T. J. Hypertens. 2000, 18, 
655. 
 (4) Halliwell, B. Plant Physiol. 2006, 141, 312.  
 (5) Libby, P.; Ridker, P. M. Nature 2011, 473, 317. 
 (6) National Heart, Lung, and Blood Institute: What is atherosclerosis? 
http://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis/(accessed 
04/12/2012), 2011. 
 (7) Berliner, J. A.; Navab, M.; Fogelman, A. M.; Frank, J. S.; Demer, L. 
L.; Edward, P. A.; Watson, A. D.; Lusis, A. J. Circulation 1995, 91, 2488.  
 (8) Berliner, J. A.; Watson, A. D. N. Engl J. Med. 2005, 353. 
 (9) Wilcox, C. S.; Pearlman, A. Pharmacol. Rev. 2008, 60, 418.  
 (10) Lakshmi, S. V. V.; Padmaja, G.; Kuppusamy, P.; Kutala, V. K. 
Indian J. Biochem. Bio. 2009, 46, 421. 
 (11) Heistad, D. D. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 689.  
 (12) Thomas, C. E.; Kalyanaraman, B. Oxygen Radicals And The Disease 
Process; Harwood Academic Publishers, 1997, 237 – 239. 
 (13) Miguel, M.; Cordero, M.D.; Oxidative Therapy Against Cancer. In 
Oxidative Stress and Diseases; InTech, 2012, 497 – 498. 
 (14) Spitz, D. R. Oxidative Stress In Applied Basic Research And Clinical 
Practice; Humana press: New York, 2012, p61. 
References 
131 
 
 (15) Halliwell, B.; Gutteridge, J. M. C. Free Radicals In Biology And 
Medicine; Third ed.; Oxford University Press, 1999, 689 – 696. 
 (16) Storz, P. Front.  Biosci. 2005, 10, 1881.  
 (17) Lee, J.; Koo, N.; Min, D. B. Compr. Rev Food sci. F.  2004, 3, 21  
 (18) Sharma, A.; Kaur, P.; Kumar, B.; Prabhakar, S.; Gill, K. D. 
Parkinsonism Relat. D.  2008, 14, 52. 
 (19) Zhang, J.; Perry, G.; Smith, M. A.; Robertson, D.; Olson, S. J.; 
Graham, D. G.; Montine, T. J. Am. J. Pathol. 1999, 154, 1423. 
 (20) Gonsette, R. E. J. Neurol. Sci. 2008, 274, 48. 
 (21) Kamsler, A.; Daily, D.; Hochman, A.; Stern, N.; Shiloh, Y.; Rotman, 
G.; Barzilai, A. Cancer Res. 2001, 61, 1849. 
 (22) Nuttal, S. L.; Kendall, M. J.; Martin, U. Q. J. med. 1999, 92, 239.  
 (23) Stocco, B.; Toledo, K.; Salvador, M.; Paulo, M.; Koyama, N.; Toloi, 
M. R. T. Maturitas 2012, 72, 72. 
 (24) Martin, A. Nutr. Rev. 2003, 61, 69. 
 (25) Etminan, M.; Gill, S. S.; Samii, A. Lancet Neurol. 2005, 4, 362. 
 (26) Johnson, S. Med. Hypotheses 2000, 55, 239. 
 (27) Vivekananthan, D. P.; Penn, M. S.; Sapp, S. K.; Hsu, A.; Topol, E. J. 
The Lancet 2003, 361, 2017.  
 (28) Petrovski, G.; Gurusamy, N.; Das, D. K. Ann.NY.Acad. Sci.  2011, 
1215, 22. 
 (29) Iervasi, G.; Forini, F.; Sabatino, L. Crit. Care Med. 2012, 40, 3098.  
 (30) Powell, R. G.; Tepaske, M. R.; Plattner, R. D.; White, J. F.; Clement, 
S. L. Phytochemistry 1994, 35, 335. 
 (31) de la Lastra C. A.; Villegas, I. Biochem. Soc. Trans. 2007, 35, 1156. 
References 
132 
 
 (32) Stewart, J. R.; Artime, M. C.; Obrian, C. A. J. Nutr. 2003, 133, 
2440S.  
 (33) Figueiras, T., S.; Neves-petersen, M. T.; Petersen, S. B. J Fluoresc.  
2011, 21, 1897.  
 (34) Kopp, P. Eur. J. Endocrinol. 1998, 138, 619.  
 (35) Baur, J. A.; Sinclair, D. A. Nat. Rev. Drug Discov. 2006, 5, 493. 
 (36) Donez, D.; Jeandet, P.; Clement, C.; Courot, E. Trends Biotechnol. 
2009, 27, 706.  
 (37) Bradamante, S.; Barenghi, L.; Villa, A. Cardiovasc. Drug Rev. 2004, 
22, 169.  
 (38) King, R. E.; Bomser, J. A.; Min, D. B. Compr. Rev.  Food sci.F. 
2006, 5, 65.  
 (39) Pervaiz, S. FASEB J. 2003, 17, 1975.  
 (40) Naderalli, E. K.; Doyle, P. J.; Williams, G. Clin. Sci. 2000, 98, 537.  
 (41) Wu, J. M.; Hsieh, T. Ann. NY.  Acad. Sci. 2011, 1215, 16.  
 (42) Arnal, N.; Tacconi de Alaniz, M. J.; Marra, C. A. Food 
Chem.Toxicol. 2012, 50, 415  
 (43) Leonard, S. S.; Xia, C.; Jiang, B.; K, G.; Shi, X. Biochem. Bioph Res. 
Co. 2003, 309, 1017. 
309, 1017.  
 (44) Belguendouz, L.; Fremont, L.; Linard, A. Biochemical. Pharmacol. 
1997, 53, 1347.  
 (45) Wang, H.; Yang, Y.; Qian, H.; Zhang, Q.; Xu, H.; Li, J. Heart fail. 
Rev. 2012, 17, 437.  
References 
133 
 
 (46) Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; 
Beecher, C. W. W.; Fong, H. H. S.; Farnsworth, N. R.; et al. Science 1997, 275, 218.  
 (47) Pezzuto, J. M. Pharm. Biol. 2008, 46, 443.  
 (48) Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; 
Shishodia, S.; Takada, Y. Anticancer Res. 2004, 24, 2783.  
 (49) Al-Abd, A. M.; Mahmoud, A. M.; El-Sherbiny, G. A.; El-Moselhy, 
M. A.; Nofal, S. M.; El-Latif, H. A.; El-Eraky, W. I.; El-Shemy, H. A. Cell 
Proliferat. 2011, 44, 591. 
 (50) Lu, R.; Serrero, G. J. Cell. Physiol. 1999, 179, 297. 
 (51) Nakagawa, H.; Kiyozuka, Y.; Uemura, Y.; Senzaki, H.; Shikata, N.; 
Hioki, K.; Tsubura, A. J. Cancer Re.s Clin. Oncol. 2001, 127, 258.  
 (52) Keddie, D. J.; Fairfull-Smith, K. E.; Bottle, S. E. Org. Biomol. Chem. 
2008, 6, 3135. 
 (53) Tang, F.; Su, Y.; Chen, N.; Hsieh, H.; Chen, K. Mol. Nutr.Food Res. 
2008, 52, 683.  
 (54) Bove, K.; Lincoln, D. W.; Tsan, M. Biochem. Bioph. Res. Co. 2002, 
291, 1001.  
 (55) Vanamala, J.; Radhakrishnan, S.; Reddivari, L.; Bhat, V. B.; Ptitsyn, 
A. Proteome Sci. 2011, 9, 49. 
 (56) Juan, M. E.; Alfaras, I.; Planas, J. M. Pharmacol. Res. 2012, 65, 584.  
 (57) Meng, L.; Sefah, K.; Odonoghue, M. B.; Zhu, G.; Shangguan, D.; 
Noorali, A.; Chen, Y.; Zhou, L.; Tan, W. PLoS One 2010, 5, e14018.  
 (58) Ratan, H. L.; Steward, W. P.; Gescher, A. J.; Mellon, J. K. Urol. 
Oncol. 2002, 7, 223. 
References 
134 
 
 (59) Fang, Y.; DeMarco, V. G.; Nicholl, M. B. Cancer Sci. 2012, 103, 
1090. 
 (60) Marambaud, P.; Zhao, H.; Davies, P. J. Biol. Chem. 2005, 280, 
37377. 
 (61) Karuppagounder, S. S.; Pinto, J. T.; Xu, H.; Chen, H.-L.; Beal, M. F.; 
Gibson, G. E. Neurochem. Int. 2009, 54, 111. 
 (62) Sun, A. Y.; Wang, Q.; Simonyi, A.; Sun, G. Y. Mol. Neurobiol. 2010, 
41, 375. 
 (63) Jin, F.; Wu, Q.; Lu, Y.-F.; Gong, Q.-H.; Shi, J.-S. Eur. J. Pharmacol. 
2008, 600, 78. 
 (64) Khan, M. M.; Ahmad, A.; Ishrat, T.; Khan, M. B.; Hoda, M. N.; 
Khuwaja, G.; Raza, S. S.; Khan, A.; Javed, H.; Vaibhav, K.; Islam, F. Brain Res. 
2010, 1328, 139. 
 (65) Ho, D. J.; Calingasan, N. Y.; Wille, E.; Dumont, M.; Beal, M. F. Exp. 
Neurol. 2010, 225, 74. 
 (66) Pasinetti, G. M.; Wang, J.; Marambaud, P.; Ferruzzi, M.; Gregor, P.; 
Knable, L. A.; Ho, L. Exp. Neurol. 2011, 232, 1. 
 (67) Maher, P.; Dargusch, R.; Bodai, L.; Gerard, P. E.; Purcell, J. M.; 
Marsh, J. L. Hum. Mol. Genet. 2011, 20, 261. 
 (68) Rocha-Gonzalez, H. I.; Ambriz-Tututi, M.; Granados-Soto, V. CNS 
Neurosci. Ther. 2008, 14, 234. 
 (69) Shindler, K. S.; Ventura, E.; Dutt, M.; Elliott, P.; Fitzgerald, D. C.; 
Rostami, A. J Neuro-ophthalmol.  2010, 30, 328. 
 (70) Halliwell, B. J. Roy. Soc. Med. 1989, 82, 747. 
 (71) Tebben, L.; Studer, A. Angew. Chem. int. Ed. 2011, 50, 5034.  
References 
135 
 
 (72) Morrow, B. J., The Synthesis of Novel Nitroxides and their 
Application as Small-Molecule Antioxidants and Profluorescent Probes for 
Oxidative Stress. Ph.D Disertation, Queensland University of Technology, 2010. 
 (73) Hicks, R. G. Org. Biomol. Chem. 2007, 5, 1321. 
 (74) Nonhebel, D. C.; Tedder, J. M. Radicals; Cambridge University 
Press, 1979. 
 (75) Keddie, D. J., The Synthesis of Novel Profluorescent Nitroxide 
Probes .Ph.D. Disertation, Queensland University of Technology, Brisbane, 2008. 
 (76) Fairfull-Smith, K. E.; Blinco, J. P.; Keddie, D. J.; George, G. A.; 
Bottle, S. E. Macromolecules 2008, 41, 1577. 
 (77) Fairfull-Smith, K. E.; Bottle, S. E. Eur. J. Org. Chem. 2008, (32) 
5391. 
 (78) Aronovitch, Y.; Godinger, D.; Israeli, A.; Krishna, M. C.; Samuni, 
A.; Goldstein, S. Free Radical Biol. Med. 2007, 42, 1317. 
 (79) Soule, B. P.; Hyodo, F.; Matsumoto, K.-I.; Simone, N. L.; Cook, J. 
A.; Krishna, M. C.; Mitchell, J. B. Free Radical Biol. Med. 2007, 42, 1632. 
 (80) Soule, B. P.; Hyodo, F.; Matsumoto, K.-I.; Simone, N. L.; Cook, J. 
A.; Krishna, M. C.; Mitchell, J. B. Antioxid. Redox Sign. 2007, 9, 1731. 
 (81) Bar-On, P.; Mohsen, M.; Zhang, R.; Feigin, E.; Chevion, M.; 
Samuni, A. J. Am. Chem. Soc. 1999, 121, 8070. 
 (82) Yin, H.; Xu, L.; Porter, N. A. Chem. Rev.  2011, 111, 5944. 
 (83) Krishna, M. C.; Samuni, A.; Taira, J.; Goldstein, S.; Mitchell, J. B.; 
Russo, A. J. Biol. Chem. 1996, 271, 26018. 
 (84) Hahn, S. M.; DeLuca, A. M.; Coffin, D.; Krishna, C. M.; Mitchell, J. 
B. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 839. 
References 
136 
 
 (85) Rees, M. D.; Bottle, S. E.; Fairfull-Smith, K. E.; Malle, E.; 
Whitelock, J. M.; Davies, M. J. Biochem. J. 2009, 421, 79. 
 (86) Gariboldi, M. B.; Terni, F.; Ravizza, R.; Meschini, S.; Marra, M.; 
Condello, M.; Arancia, G.; Monti, E. Free Radical Biol. Med. 2006, 40, 1409. 
 (87) Gariboldi, M. B.; Lucchi, S.; Caserini, C.; Supino, R.; Oliva, C.; 
Monti, E. Free Radical Biol. Med. 1998, 24, 913. 
 (88) Schubert, R.; Erker, L.; Barlow, C.; Yakushiji, H.; Larson, D.; Russo, 
A.; Mitchell, J. B.; Wynshaw-Boris, A. Hum. Mol. Genet. 2004, 13, 1793. 
 (89) Suy, S.; Mitchell, J. B.; Samuni, A.; Mueller, S.; Kasid, U. Cancer 
2005, 103, 1302. 
 (90) Butterfield, D. A.; Drake, J.; Pocernich, C.; Castegna, A. Trends Mol. 
Med. 2001, 7, 548. 
 (91) Chonpathompikunlert, P.; Han, J.; Toh, K.; Isoda, H.; Nagasaki, Y. 
Eur. J. Pharmacol. 2011, 650, 544. 
 (92) Liang, Q.; Smith, A. D.; Pan, S.; Tyurin, V. A.; Kagan, V. E.; 
Hastings, T. G.; Schor, N. F. Biochem. Pharmacol. 2005, 70, 1371. 
 (93) Kalai, T.; Borza, E.; Antus, C.; Radnai, B.; Gulyas-Fekete, G.; Feher, 
A.; Suemegi, B.; Hideg, K. Bioorg. Med. Chem. 2011, 19, 7311. 
 (94) Wilcox, C. S.; Pearlman, A. Pharmacol. Rev. 2008, 60, 418. 
 (95) Berry, C.; Brosnan, M. J.; Fennell, J.; Hamilton, C. A.; Dominiczak, 
A. F. Curr. Opin. Nephrol. Hy.  2001, 10, 247. 
 (96) Simonsen, U.; Christensen, F. H.; Buus, N. H. Pharmacol. Ther. 
2009, 122, 109. 
 (97) Welch, W. J.; Mendonca, M.; Blau, J.; Karber, A.; Dennehy, K.; 
Patel, K.; Lao, Y. S.; Jose, P. A.; Wilcox, C. S. Kidney Int. 2005, 68, 179. 
References 
137 
 
 (98) Adeagbo, A. S. O.; Joshua, I. G.; Fatkner, C.; Matheson, P. J. Eur. J. 
Pharmacol.y 2003, 481, 91. 
 (99) Fremont, L. Life Sci. 2000, 66, 663. 
 (100) Chen, C. K.; Pace-Asciak, C. R. Gen. Pharmacol. 1996, 27, 363. 
 (101) Rush, J. W. E.; Quadrilatero, J.; Levy, A. S.; Ford, R. J. Exp. Biol. 
Med. 2007, 232, 814. 
 (102) Liu, Z. P.; Song, Y.; Zhang, X. P.; Liu, Z. Q.; Zhang, W. Z.; Mao, W. 
F.; Wang, W.; Cui, W. M.; Zhang, X.; Jia, X. D.; Li, N.; Han, C.; Liu, C. Clin. Exp. 
Pharmacol. P. 2005, 32, 1049. 
 (103) Chan, V.; Fenning, A.; Iyer, A.; Hoey, A.; Brown, L. Curr. Pharm. 
Biotechnol. 2011, 12, 429. 
 (104) Wang, Q.; Xu, J.; Rottinghaus, G. E.; Simonyi, A.; Lubahn, D.; Sun, 
G. Y.; Sun, A. Y. Brain Res. 2002, 958, 439. 
 (105) Ishida, S.; Matsumoto, S.; Yokoyama, H.; Mori, N.; Kumashiro, H.; 
Tsuchihashi, N.; Ogata, T.; Yamada, M.; Ono, M.; Kitajima, T.; et, a. Magn. Reson. 
Imaging 1992, 10, 109. 
 (106) Griffiths, P. G.; Moad, G.; Rizzardo, E.; Solomon, D. H. Aust. J. 
Chem. 1983, 36, 397. 
 (107) Khan, N.; Blinco, J. P.; Bottle, S. E.; Hosokawa, K.; Swartz, H. M.; 
Micallef, A. S. J. Magn. Reson. 2011, 211, 170. 
 (108) Fairfull-Smith, K. E.; Brackmann, F.; Bottle, S. E. Eur J Org. Chem. 
2009, 12, 1902. 
 (109) Farina, A.; Ferranti, C.; Marra, C. Nat. Prod. Res. 2006, 20, 247. 
 (110) Morales-Serna, J. A.; Zuniga-Martinez, A.; Salmon, M.; Gavino, R.; 
Cardenas, J. synthesis 2012, 44, 446. 
References 
138 
 
 (111) Morris, J. C., A 'Click Approach' to the Generation of Novel 
Profluorescent Nitroxide. Master's Disertation, Queensland University of 
Technology, 2011. 
 (112) Perry, C. J.; Parveen, Z. J.Chem. Soc., Perkin Trans.2  2001, 4, 512.  
 (113) Hsieh, J.; Cheng, C.-H. Chem. Commun. 2005, (36), 4554. 
 (114) Griffith, P. G.; Moad, G.; Rizzardo, E.; Solomon, D. H. Aust. J. 
Chem. 1983, 36, 397. 
 (115) Micallef, A. S.; Bott, R. C.; Bottle, S. E.; Smith, G.; White, J. M.; 
Matsuda, K.; Iwamura, H. J. Chem. Soc., Perkin Trans. 2 1999, 65. 
 (116) Micallef, A. S., Novel Nitroxides and Pronitroxides-Synthesis and 
Properties of New Spin Traps and Spin Probes with Potential for Biological 
Application. PhD. Disertation, Queensland University of Technology, 2000. 
 (117) Bottle, S. E.; Blinco, J.; George, G.; Micallef, A.; Wade, T.; 
Queensland University of Technology, Australia . 2007, p 122pp. 
 (118) Li, Y.; Lei, X.; Li, X.; Lawler, R. G.; Murata, Y.; Komatsu, K.; 
Turro, N. J. Chem. Commun 2011, 47. 
 (119) Blinco, J. P.; Hodgson, J. L.; Morrow, B. J.; Walker, J. R.; Will, G. 
D.; Coote, M. L.; Bottle, S. E. J. Org. Chem. 2008, 73, 6763. 
 (120) Hart, H.; Nwokogu, G. C. Tetrahedron Lett. 1983, 24, 5721. 
 (121) Clayden, J.; Greeves, N.; Warren, S.; Wothers, P. Organic 
Chemistry; Oxford University Press, 2008. 
 (122) Castanet, A.-S.; Colobert, F.; Broutin, P.-E. Tetrahedron Lett. 2002, 
43, 5047. 
 (123) Patil, B. R.; Bhusare, S. R.; Pawar, R. P.; Vibhute, Y. B. Tetrahedron 
Lett. 2005, 46, 7179. 
References 
139 
 
 (124) Prakash, G. K. S.; Mathew, T.; Hoole, D.; Esteves, P. M.; Wang, Q.; 
Rasul, G.; Olah, G. A. J. Am. Chem. Soc. 2004, 126, 15770.  
 (125) Skulski, L. Molecules 2000, 5, 1331  
 (126) Makarov, S. G.; Maksimova, K. N.; Baranov, E. V.; Fukin, G. K.; 
Suvorova, o. N.; Wohrle, D.; Domrachev Russ. Chem. Bull., int.Ed 2006, 55. 
 (127) Tellenbroker, J.; Kuck, D. Eur. J. Org. Chem. 2001, 1483. 
 (128) Kraszkiewicz, L.; Sosnowski, M.; Shukski, L. synthesis 2006, 1195.  
 (129) Bruice, P. Y. Organic Chemistry; 6 ed.; Pearson, 2004. 
 (130) Barrett, A. G. M.; Hanson, G. R.; White, A. J. P.; Williams, D. J.; 
Micallef, A. S. Tetrahedron 2007, 63, 5244. 
 (131) Golubev, V. A.; Sholle, V. D.; Rozantsev, E. G. Izv. Akad. Nauk 
SSSR, Ser. Khim. 1972, 1202. 
 (132) Blinco, J. P.; Hodgson, J. L.; Morrow, B. J.; Walker, J. R.; Will, G. 
D.; Coote, M. L.; Bottle, S. E. J. Org. Chem 2008, 73. 
 (133) Mizoroki, T.; Mori, K.; Ozaki, A. Bull. Chem. Soc. Jap. 1971, 44, 
581. 
 (134) Cabri, W.; Candiani, I. Acc. Chem. Res. 1995, 28, 2. 
 (135) Laue, T.; Plagens, A. 2005; 2 ed.; Wily-Interscience, 2005, 155 – 
161. 
 (136) Wyatt, P.; Warren, S. G. Organic Synthesis: Strategy and Control; 1 
ed.; John Wily: Hoboken, 2007, 307 – 339. 
 (137) Wittig, G.; Schoellkopf, U. Org. Synth. 1960, 40, 66. 
 (138) Farina, A.; Ferranti, C.; Marra, C.; Guiso, M.; Norcia, G. Nat. Prod. 
Res. 2007, 21, 564. 
 (139) Guiso, M.; Marra, C.; Farina, A. Tetrahedron Lett. 2002, 43, 597. 
References 
140 
 
 (140) Colwell, J. M.; Walker, J. R.; Blinco, J. P.; Micallef, A. S.; George, 
G. A.; Bottle, S. E. Polym. Degrad. Stab. 2010, 95, 2101. 
 (141) Vanysek, P.; Electrochemical series. 
http://downloads.gphysics.net/UACh/Medicina/TablasIones.pdf (accessed 
04/06/2013), 2000. 
 (142) Greene, T. W.; Wuts, P. G. M. Protecting Groups in Organic 
Synthesis; Third ed.; John Wiley & Sons, Inc.: New York, 1999, 277. 
 (143) Iyer, A.; Chan, V.; Brown, L. Curr. Cardiol. Rev. 2010, 6, 291. 
 (144) Costa, C. A.; Amara, T. A. S.; Carvalho, L.; Ognibene, D. T.; da 
Silva, A. F. E.; Moss, M. B.; Valenca, S. S.; de Moura, R. S.; Resende, A. C. Am. J. 
Hypertens. 2009, 22, 1242. 
 (145) Fenning, A.; Harrison, G.; Rose'meyer, R.; Hoey, A.; Brown, L. Am. 
J. Physiol. 2005, 289, H1408. 
 (146) Ventura, H. O.; Messerli, F. H.; Barron, R. E. J.Hypertens. 1986, 4, 
265. 
 (147) Martin, J. F.; Schneider, A. M.; Smith, N. T. Ieee T.Bio-med. Eng. 
1987, 34, 603. 
 (148) Marx, L.; Chiarelli R.; Guiberteu, T.; Rassat A. J. Chem. Soc., Perkin 
Trans. 1 2000, 1181.  
 
 
